

AMERICAN PSYCHIATRIC ASSOCIATION CONTINUING MEDICAL EDUCATION POLICY ON FULL DISCLOSURE

The American Psychiatric Association requires disclosure, by presenters at CME activities, of any significant financial or other affiliation with commercial organization(s) regulated by the Food and Drug Administration, which may have a direct or indirect interest in the subject matter of the scientific program. A "financial interest" may include, but is not limited to, being a shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization. An "affiliation" may include, holding a position on an advisory committee or some other role or benefit to a supporting organization.

Under the ACCME Standards for Commercial Support that were in effect when the 2005 Annual Meeting was planned, the existence of such relationships does not necessarily constitute a conflict of interest; but the prospective audience must be informed of the presenter's affiliation with every commercial supporter by an acknowledgement in the printed program and verbal or visual disclosure to participants at the session (disclosure by slide or overhead is required if audiovisual equipment is used for the presentation). This policy is intended to openly identify any potential conflict(s) so that members of the audience in an educational activity are able to form their own judgments about the presentation. The APA also requires verbal disclosure of discussion of unlabeled uses of a commercial product or investigational use of a product not yet approved for this purpose.

The list of presenters below have indicated that either they or an immediate family member has a significant interest or other affiliation with a commercial supporter of this meeting and/or with the manufacturer(s) of a commercial product(s) and/or provider of commercial services(s). The presenter's name and the company's name are listed, along with the page number the presenter appears on in this *Program Book*. The nature of the presenter's relationship with the disclosed company is indicated by the following code: consultant or advisory board¹, full-time employment², research/grant support³, speakers' bureau⁴, stock or other financial options⁵, other financial or business relationships⁶. If a number has not been assigned, the presenter has not disclosed the relationship to the company.

The second list of presenters, beginning on page XXXVI, have indicated neither they nor an immediate family member has any significant relationship to disclose. Voting member of the Board of Trustees, Assembly officers, and member of the Scientific Program Committee cannot receive honoraria or travel reimbursement for participating in Industry-Supported Symposia.

| Presenter | Manufacturer(s) | Program Page # |
|------------------------------|---|----------------|
| Gene G. Abel, M.D. | Abel Screening, Inc. ⁶ ; Institute for Child Molestation Research and Prevention ⁶ | 41 |
| Donald E. Addington, M.D. | Eli Lilly and Company ³ | 71 |
| Marilyn Ader, Ph.D. | Janssen Pharmaceutica Products, LP. ^{1,3} | 7 |
| Nassima Ait-Daoud, M.D. | Ortho McNeil Pharmaceutical Inc. ¹ | 31, 56 |
| Hagop S. Akiskal, M.D. | GlaxoSmithKline ⁴ ; Abbott Laboratories, Inc. ⁴ ; Eli Lilly and Company ⁴ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ⁴ ; Bristol-Myers Squibb ⁴ ; Pfizer Inc. ⁴ ; AstraZeneca Pharmaceuticals ⁴ ; Janssen Pharmaceutica Products, LP. ⁴ | 28 |
| George S. Alexopoulos, M.D. | Forest Pharmaceuticals, Inc. ^{1,3,4} ; Cephalon Inc. ^{3,4} ; Janssen Pharmaceutica Products, LP. ⁴ ; Pfizer Inc. ⁴ ; Lilly Research Laboratories, a division of Eli Lilly and Company ⁴ ; Bristol-Myers Squibb ⁴ ; Meyers ⁴ ; GlaxoSmithKline ⁴ | 6, 11 |
| Jon G. Allen, Ph.D. | American Psychiatric Publishing, Inc. ⁶ | 20 |
| Michael H. Allen, M.D. | Abbott Laboratories, Inc. ^{1,3,4} ; Janssen Pharmaceutica Products, LP. ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; GlaxoSmithKline ^{1,4} ; Bristol-Myers Squibb ^{1,3} ; Pfizer Inc. ^{1,4} ; Novartis Pharmaceuticals Corporation ³ ; AstraZeneca Pharmaceuticals ^{1,4} ; Alexza ¹ | 12 |
| Jonathan E. Alpert, M.D. | Organon Pharmaceuticals Inc. ^{3,4} ; Parmanite ³ ; Eli Lilly and Company ³ ; Forest Pharmaceuticals, Inc. ³ ; Aspect Medical Systems, Inc. ³ ; Pfizer Inc. ³ | 4 |
| Sonia Ancoli-Israel, Ph.D. | King Pharmaceutical ⁴ ; Takeda Pharmaceuticals ^{4,1} ; Neurocrine Biosciences Inc. ¹ ; Sepracor Inc. ¹ | 9, 36 |
| Allan A. Anderson, M.D. | Pfizer Inc. ⁴ ; Novartis Pharmaceuticals Corporation ⁴ ; Janssen Pharmaceutica Products, LP. ⁴ ; Forest Pharmaceuticals, Inc. ⁴ | 49 |
| Raymond F. Anton, Jr., M.D. | Bristol-Myers Squibb ^{1,3} ; Ortho McNeil Pharmaceutical Inc. ^{1,3,4} ; Alkermes Pharmaceuticals ¹ ; Pfizer Inc. ^{1,3} | 31, 62 |
| Jose C. Appolinario, M.D. | Janssen Pharmaceutica Products, LP. ³ ; Abbott Laboratories, Inc. ³ | 59 |
| Michael R. Arambula, M.D. | Pfizer Inc. ⁴ ; AstraZeneca Pharmaceuticals ⁴ | 35 |
| Kimberly A. Arlinghaus, M.D. | UCB Pharmaceuticals ¹ ; Bristol-Myers Squibb ³ ; Abbott Laboratories, Inc. ³ ; Pfizer Inc. ^{3,4} ; Forest Pharmaceuticals, Inc. ^{3,4} ; Wyeth Pharmaceuticals ^{3,4} ; AstraZeneca Pharmaceuticals ^{3,4} ; Janssen Pharmaceutica Products, LP. ^{3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} | 49 |
| Scott C. Armstrong, M.D. | Pfizer Inc. ⁴ ; Lilly Research Laboratories, a division of Eli Lilly and Company ⁴ ; Janssen Pharmaceutica Products, LP. ⁴ ; Forest Pharmaceuticals, Inc. ⁴ | 41 |

DISCLOSURE INDEX

| Presenter | Manufacturer(s) | Program Page # |
|-----------------------------|---|-----------------------|
| Lesley M. Arnold, M.D. | Pfizer Inc. ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Wyeth Pharmaceuticals ^{3,4} ; Cypress Bioscience Inc. ^{1,3,4} | 10, 39 |
| Darryl Atherholt | Janssen Pharmaceutica Products, LP ² | 44 |
| Evelyn Attia, M.D. | Pfizer Inc. ³ | 59 |
| Alan A. Axelson, M.D. | Pfizer Inc. ⁴ ; Lilly Research Laboratories, a division of Eli Lilly and Company ⁴ ; Highmeirtz Blue Cross Blue Shield ¹ | 17 |
| Rahn K. Bailey, M.D. | Eli Lilly and Company ⁴ ; Janssen Pharmaceutica Products, LP ⁴ ; Bristol-Myers Squibb ⁴ | 66 |
| F. M. Baker, M.D. | Pfizer Inc. ⁴ | 79, 92 |
| Claudia F. Baldassano, M.D. | Elan Pharmaceuticals ³ ; AstraZeneca Pharmaceuticals ^{1,4} ; GlaxoSmithKline ⁴ ; Eli Lilly and Company ⁴ | 5, 13 |
| John J. Barry, M.D. | GlaxoSmithKline ^{1,4} ; Neuropace ^{1,4} ; Cyberonics, Inc. ¹ | 95 |
| Bernard D. Beitman, M.D. | Pfizer Inc. ⁴ ; GlaxoSmithKline ⁴ | 27, 68, 93 |
| Ruth M. Benca, M.D. | Takeda Pharmaceuticals ^{1,3,4} ; Wyeth Pharmaceuticals ^{1,4} ; Neurocrine Biosciences Inc. ^{1,4} ; Pfizer Inc. ^{1,4} ; Sepracor Inc. ^{1,4} ; Sanofi-Synthelabo Pharmaceuticals, Inc. ^{1,4} ; King ^{1,4} | 36 |
| Dimitri Bennett, M.D. | GlaxoSmithKline ² | 54 |
| Sarah Berga, M.D. | Wyeth Pharmaceuticals ¹ ; Cerma ¹ ; Novogyn ¹ | 46 |
| Laura A.C. Berman, Ph.D. | Bayer Corporation, Pharmaceutical Division ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Medtronic ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Proctor & Gamble ^{1,3,4} ; Ortho McNeil Pharmaceutical Inc. ^{1,3,4} ; Solvay Pharmaceuticals, Inc. ^{1,3,4} | 75 |
| John L. Beyer, M.D. | Eli Lilly and Company ^{1,4} ; GlaxoSmithKline ³ ; Eisai, Inc. ³ ; Boehringer-Ingelheim Pharmaceuticals ³ | 85 |
| Joseph Biederman, M.D. | Celltech Pharmaceuticals, Ltd ¹ ; Noven Pharmaceutical ¹ ; Johnson and Johnson PRD ¹ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3} ; Pfizer Inc. ^{1,3} ; Cephalon Inc. ^{1,3} ; Novartis Pharmaceuticals Corporation ^{1,4} ; Shire US Inc. ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Ortho McNeil Pharmaceutical Inc. ^{1,3,4} ; National Institute of Mental Health ³ ; Stanley Foundation ³ ; National Institute on Drug Abuse ³ ; Wyeth Pharmaceuticals ⁴ | 12, 48, 57, 80 |
| Angela Birnbaun, M.D. | Ovation Pharmaceuticals ¹ ; UCB Pharmaceuticals ¹ | 80 |
| Carlos Blanco-Jerez, M.D. | Pfizer Inc. ³ | 3 |
| Michael Blumenfeld, M.D. | Pfizer Inc. ^{3,4} ; Forest Pharmaceuticals, Inc. ³ ; Shire Ridgewood Pharmaceuticals ^{1,4} | 14 |
| William Blumentals, Ph.D. | Proctor & Gamble Pharmaceuticals ² | 54 |
| Curley Bonds, M.D. | Pfizer Inc. ⁴ ; Abbott Laboratories, Inc. ^{1,4} | 76 |
| Howard E. Book, M.D. | The American Psychological Association Press ⁶ | 5, 8, 93 |
| Charles L. Bowden, M.D. | Abbott Laboratories, Inc. ^{1,3,4} ; AstraZeneca Pharmaceuticals ⁴ ; Bristol-Myers Squibb ³ ; Elan Pharmaceuticals ³ ; GlaxoSmithKline ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; National Institute of Mental Health ³ ; Parke Davis ³ ; Pfizer Inc. ⁴ ; R.W. Johnson Pharmaceuticals Institute ³ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ¹ ; Smith Kline Beecham ³ ; Stanley Foundation ³ ; UCB Pharmaceutical, Inc. ¹ | 55, 76 |
| Theron C. Bowers, Jr., M.D. | AstraZeneca Pharmaceuticals ⁴ | 25, 45 |
| John M. Bradford, M.B. | Pfizer Inc. ⁴ | 41 |
| Kathleen T. Brady, M.D. | Pfizer Inc. ^{1,4} ; Eli Lilly and Company ^{1,4} ; Abbott Laboratories, Inc. ^{1,3,4} ; Forest Pharmaceuticals, Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Wyeth Pharmaceuticals ³ | 2, 31 |
| William Breitbart, M.D. | Cephalon Inc. ^{1,4} | 49 |
| J. Douglas Bremner, M.D. | GlaxoSmithKline ^{1,3} | 20, 60 |
| Ronald Brenner, M.D. | Bristol-Myers Squibb ³ ; Eli Lilly and Company ³ ; Janssen Pharmaceutica Products, LP ³ | 43 |
| E. Sherwood Brown, M.D. | AstraZeneca Pharmaceuticals ³ ; GlaxoSmithKline ³ ; Forest Pharmaceuticals, Inc. ³ ; Bristol-Myers Squibb ^{1,3} | 36 |
| Thomas E. Brown, Ph.D. | Janssen Pharmaceutica Products, LP ^{1,4} ; Novartis Pharmaceuticals Corporation ^{1,4} ; Shire Ridgewood Pharmaceuticals ^{1,4} ; McNeil Consumer Healthcare ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} | 1, 5, 51 |
| Robert W. Buchanan, M.D. | Janssen Pharmaceutica Products, LP ³ ; Organon Pharmaceuticals Inc. ¹ | 62, 80 |
| Peter F. Buckley, M.D. | Abbott Laboratories, Inc. ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Eli Lilly and Company ¹ ; Bristol-Myers Squibb ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Novartis Pharmaceuticals Corporation ^{1,3,4} ; Pfizer Inc. ^{1,3,4} | 12, 36, 68 |
| Cathy L. Budman, M.D. | Eli Lilly and Company ^{3,4} | 68 |
| Don Buesching, Ph.D. | Eli Lilly and Company ² | 25 |
| Stephen E. Buie, M.D. | Wyeth Pharmaceuticals ⁴ | 74 |
| Cynthia M. Bulik, Ph.D. | Ortho McNeil Pharmaceutical Inc. ⁴ ; Power Changes LLC ⁶ | 6, 59, 71 |
| Kathryn A. Burns, M.D. | Eli Lilly and Company ¹ | 49 |

| Presenter | Manufacturer(s) | Program Page # |
|--------------------------------|---|------------------------|
| George Bush, M.D. | Eli Lilly and Company ^{1,3} ; Pfizer Inc. ³ ; Janssen Pharmaceutica Products, LP ³ ; Johnson and Johnson PRD ^{3,6} ; Novartis Pharmaceuticals Corporation ⁶ ; Shire Ridgewood Pharmaceuticals ⁶ ; McNeil Consumer Helathcare ⁶ | 12 |
| Marian I. Butterfield, M.D. | Bristol-Myers Squibb ^{1,3} ; Lilly Research Laboratories, a division of Eli Lilly and Company ⁴ | 10, 20, 28, 42, 57, 82 |
| Daniel J. Buisse, M.D. | Sepracor Inc. ¹ | 53 |
| Joseph R. Calabrese, M.D. | National Institute of Mental Health ³ ; Abbott Laboratories, Inc. ^{3,1} ; Ciba-Geigy Inc. ³ ; Merck & Co., Inc. ³ ; GlaxoSmithKline ^{3,1} ; Janssen Pharmaceutica Products, LP ^{3,1} ; Lilly Research Laboratories, a division of Eli Lilly and Company ³ ; MacArthur Foundation ³ ; National Alliance for Research in Schizophrenia and Affective Disorders ³ ; Parke-Davis Pharmaceuticals ³ ; R.W. Johnson Pharmaceuticals Research Institute ^{3,1} ; Sandoz Pharmaceuticals Corporation ³ ; AstraZeneca Pharmaceuticals ¹ ; Bristol-Myers Squibb ¹ ; Eli Lilly and Company ¹ ; GlaxoSmithKline ^{3,1} ; Stanley Foundation ³ ; Tap Holdings, Inc. ^{3,1} ; UCB Pharmaceuticals ^{3,1} ; Wyeth Pharmaceuticals ³ ; Novartis Pharmaceuticals Corporation ¹ ; Parke-Davis Pharmaceuticals/Warner Lambert ¹ ; Shire Ridgewood Pharmaceuticals ¹ ; Teva Pharmaceuticals ¹ | 11, 25, 67, 76 |
| William H. Campbell, M.D. | Pfizer Inc. ⁴ | 7, 41, 65 |
| Ana E. Campo, M.D. | AstraZeneca Pharmaceuticals ⁴ ; Pfizer Inc. ⁴ ; Ortho McNeil Pharmaceutical Inc. ⁴ ; Lilly Research Laboratories, a division of Eli Lilly and Company ⁴ | 25 |
| John V. Campo, M.D. | Eli Lilly and Company ¹ ; Forest Pharmaceuticals, Inc. ³ | 14, 40 |
| Gabrielle A. Carlson, M.D. | Eli Lilly and Company ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3} ; Abbott Laboratories, Inc. ^{1,3} | 36 |
| Linda L. Carpenter, M.D. | Organon Pharmaceuticals Inc. ^{1,4} ; Cephalon Inc. ^{1,3} ; GlaxoSmithKline ¹ ; Pfizer Inc. ^{1,3,4} ; National Institute of Mental Health ³ ; US Dept of Defense ³ ; Cyberonics, Inc. ^{3,4} ; Merck & Co., Inc. ^{3,4} ; Corcept Therapeutics ³ ; Medtronics ³ ; UCB Pharmaceuticals ³ ; Somerset Pharmaceuticals Inc. ⁴ ; AstraZeneca Pharmaceuticals ⁴ | 4, 37 |
| Diana Carter , M.S. | GlaxoSmithKline ³ ; Lundbeck ³ | 63 |
| David A. Casey, M.D. | Pfizer Inc. ⁴ ; Janssen Pharmaceutica Products, LP ⁴ ; Forest Pharmaceuticals, Inc. ⁴ | 47, 69 |
| Daniel Castellanos, M.D. | Janssen Pharmaceutica Products, LP ³ ; AstraZeneca Pharmaceuticals ³ | 43 |
| Ruby C. Castilla-Puentes, M.D. | GlaxoSmithKline ² | 22, 54 |
| Carlyle H. Chan, M.D. | Eli Lilly and Company ⁴ ; Forest Pharmaceuticals, Inc. ⁴ ; Pfizer Inc. ⁴ | 26, 40, 51 |
| Kiki D. Chang, M.D. | Ortho McNeil Pharmaceutical Inc. ^{1,3,4} ; Abbott Laboratories, Inc. ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,4} ; Eli Lilly and Company ^{1,4} ; GlaxoSmithKline ^{1,3,4} ; Janssen Pharmaceutica Products, LP ¹ ; Shire Ridgewood Pharmaceuticals ^{3,4} ; UCB Pharmaceuticals ¹ ; National Institute of Mental Health ³ ; Heinz C. Prechter Foundation ³ ; National Alliance for Research in Schizophrenia and Depression ³ ; Klingenstein Third Generation Foundation ³ ; American Psychiatric Association ³ | 11, 48, 76 |
| Joseph A. Cheong, M.D. | Janssen Pharmaceutica Products, LP ^{1,3,4} ; Wyeth Pharmaceuticals ^{1,3,4} ; SKB ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Organon Pharmaceuticals Inc. ^{1,3,4} ; Pfizer ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} | 46, 65, 86 |
| John A. Chiles, M.D. | Janssen Pharmaceutica Products, LP ^{3,4} ; AstraZeneca Pharmaceuticals ⁴ ; Cortex Pharmaceuticals ⁶ ; Alkermes Pharmaceuticals ⁶ ; Ivax ⁶ ; Lilly Research Laboratories, a division of Eli Lilly and Company ³ | 45 |
| Eric J. Christopher, M.D. | Janssen Pharmaceutica Products, LP ⁴ | 81 |
| Michelle O. Clark, M.D. | Eli Lilly and Company ¹ ; Pfizer Inc. ¹ | 66, 76 |
| Daniel J. Clauw, M.D. | Cypress Bioscience, Inc. ^{1,3,5} | 10 |
| Paula Clayton, M.D. | Forest Pharmaceuticals, Inc. ^{1,3,4,5} | 31 |
| Emil F. Coccaro, M.D. | Eli Lilly and Company ^{1,3,4,6} ; Abbott Laboratories, Inc. ^{1,3,6} ; GlaxoSmithKline ⁶ ; Forest Pharmaceuticals, Inc. ⁶ ; Ortho McNeil Pharmaceutical Inc. ⁶ ; AstraZeneca Pharmaceuticals ⁶ | 32 |
| Lee S. Cohen, M.D. | Berlex Laboratories, Inc. ¹ ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Ortho McNeil Pharmaceutical Inc. ¹ ; Eli Lilly and Company ^{1,3,4} ; Wyeth Pharmaceuticals ^{1,3,4} ; Pfizer Inc. ⁴ ; AstraZeneca Pharmaceuticals ^{3,4} ; Forest Pharmaceuticals, Inc. ^{3,4} ; GlaxoSmithKline ^{1,3,4} | 66 |
| Michael Cohen, B.S. | EEG Spectrum International ² | 63, 74 |
| Ian A. Cook, M.D. | Aspect Medical Systems, Inc. ³ ; Eli Lilly and Company ³ ; Pfizer Inc. ^{3,4} ; Wyeth Pharmaceuticals ⁴ | 17 |
| Gabriela Cora-Locatelli, M.D. | Pfizer Inc. ^{1,4} ; GlaxoSmithKline ⁴ | 56 |
| Suzanne Craft, Ph.D. | GlaxoSmithKline ¹ | 37 |
| Leslie J. Crofford, M.D. | Pfizer Inc. ^{1,3} ; Lilly Research Laboratories, a division of Eli Lilly and Company ¹ ; Cypress Bioscience, Inc. ¹ | 10 |
| Catherine C. Crone, M.D. | Pfizer Inc. ⁴ | 47 |

DISCLOSURE INDEX

| Presenter | Manufacturer(s) | Program Page # |
|------------------------------|---|-----------------------|
| Scott J. Crow, M.D. | Eli Lilly and Company ³ ; Ortho McNeil Pharmaceutical Inc. ^{1,3} ; Pfizer Inc. ⁴ ; GlaxoSmithKline ³ | 6 |
| Jeffrey L. Cummings, M.D. | Pfizer Inc. ^{1,4} ; Eisai, Inc. ^{1,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Novartis Pharmaceuticals Corporation ^{1,4} ; Praecis Pharmaceuticals ¹ ; Lilly Research Laboratories, a division of Eli Lilly and Company ¹ ; AstraZeneca Pharmaceuticals ¹ ; Forest Pharmaceuticals, Inc. ^{1,3,4,6} ; Bristol-Myers Squibb ¹ ; Roche Laboratories, a member of the Roche Group ¹ ; Aventis Pharmaceuticals ¹ ; Cortex Pharmaceuticals ³ ; Lundbeck ¹ ; Myriad Genetics, Inc. ¹ ; Ono Pharmaceuticals ¹ | 9, 13, 39 |
| Cheryl Davenport | Merrill Lynch ^{5,6} | 43 |
| Jonathan S. Davine, M.D. | Eli Lilly and Company ^{1,4} ; GlaxoSmithKline ^{1,4} ; Janssen Pharmaceutica Products, LP ^{1,4} ; Lundbeck ^{1,4} ; Organon Pharmaceuticals Inc. ^{1,4} ; Pfizer Inc. ^{1,4} ; Wyeth Pharmaceuticals ^{1,4} | 30, 86 |
| Lori L. Davis, M.D. | Ortho McNeil Pharmaceutical Inc. ³ ; Abbott Laboratories, Inc. ^{3,4} ; Bristol-Myers Squibb ³ ; Elan Pharmaceuticals ³ ; Forest Pharmaceuticals, Inc. ³ | 3 |
| Deborah Deas, M.D. | Pfizer Inc. ³ ; Eli Lilly and Company ⁴ | 3, 36 |
| Charles DeBattista, M.D. | Corcept Therapeutics ^{1,5} ; GlaxoSmithKline ^{3,4} ; Wyeth Pharmaceuticals ^{3,4} ; Abbott Laboratories, Inc. ^{3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{3,4} ; Pfizer Inc. ^{3,4} ; Cephalon Inc. ^{3,4} | 4 |
| Melissa P. DelBello, M.D. | Abbott Laboratories, Inc. ^{3,4} ; AstraZeneca Pharmaceuticals ^{3,4} ; Eli Lilly and Company ^{1,3,4} ; Ortho McNeil Pharmaceutical Inc. ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{3,4} ; Pfizer Inc. ^{1,3,4} ; GlaxoSmithKline ⁴ ; Bristol-Myers Squibb ^{1,4} ; Shire Ridgewood Pharmaceuticals ¹ | 3, 35, 77 |
| Pedro L. Delgado, M.D. | National Institute of Mental Health ³ ; Eli Lilly and Company ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Organon Pharmaceuticals Inc. ^{1,3,4} ; Wyeth Pharmaceuticals ^{1,3,4} ; Forest Pharmaceuticals, Inc. ³ | 55, 64 |
| Diana L. Dell, M.D. | Eli Lilly and Company ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Berlex Laboratories, Inc. ^{3,4} ; GlaxoSmithKline ^{3,4} ; Wyeth Pharmaceuticals ⁴ ; TAP Pharmaceuticals Product, Inc. ⁴ | 66 |
| Mark Demitrack, M.D. | Neuronetics, Inc. ^{2,5} ; Wyeth Pharmaceuticals ⁵ ; Eli Lilly and Company ⁵ | 84 |
| Davangere P. Devanand, M.D. | Pfizer Inc. ³ ; Wyeth Pharmaceuticals ³ ; Janssen Pharmaceutica Products, LP ¹ ; Organon Pharmaceuticals Inc. ¹ | 2 |
| Michael Devin, M.D. | Eli Lilly and Company ³ | 1 |
| Mantosh J. Dewan, M.D. | Pfizer Inc. ⁴ ; AstraZeneca Pharmaceuticals ⁴ ; GlaxoSmithKline ⁴ ; Lilly Research Laboratories, a division of Eli Lilly and Company ³ ; Janssen Pharmaceutica Products, LP ³ | 3, 18, 54, 79 |
| Andrea F. DiMartini, M.D. | National Institute of Alcohol Abuse and Alcoholism (NIAAA) ³ | 40 |
| Lisa B. Dixon, M.D. | Bristol-Myers Squibb ^{3,5} ; Pfizer Inc. ^{3,5} ; Lilly Research Laboratories, a division of Eli Lilly and Company ³ ; Janssen Pharmaceutica Products, LP ³ | 29, 55, 84, 93 |
| John P. Docherty, M.D. | Nutrition 21, Inc. ³ ; Bristol-Myers Squibb ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,4} ; Forest Pharmaceuticals, Inc. ^{3,4} ; AstraZeneca Pharmaceuticals ³ ; Abbott Laboratories, Inc. ³ ; Novartis Pharmaceuticals Corporation ³ ; GlaxoSmithKline ³ ; Eli Lilly and Company ³ | 31, 70 |
| Manfred Doepfner, M.D. | Eli Lilly and Company ⁶ | 34 |
| Martin Dossenbach, M.D. | Eli Lilly and Company ² | 89 |
| Alysa Doyle, Ph.D. | Eli Lilly and Company ¹ ; McNeil Pharmaceuticals ⁴ | 57 |
| Robert Drake, M.D. | Johnson and Johnson PRD ³ | 29 |
| Douglas A. Drossman, M.D. | Novartis Pharmaceuticals Corporation ^{1,3} ; Solvay Pharmaceuticals, Inc. ^{1,3,4} ; GlaxoSmithKline ¹ | 53 |
| Roxanne Dryden-Edwards, M.D. | Eli Lilly and Company ³ | 18 |
| Sanjay Dube, M.D. | Eli Lilly and Company ² | 28, 67 |
| David W. Dunn, M.D. | Eli Lilly and Company ^{1,3,4} ; Shire Ridgewood Pharmaceuticals ³ ; AstraZeneca Pharmaceuticals ³ ; The National Institute of Neurological Disorders and Stroke (NINDS) ³ ; O'Neil ⁴ ; UCB Pharmaceuticals ⁴ | 95 |
| David L. Dunner, M.D. | Eli Lilly and Company ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Wyeth Pharmaceuticals ^{1,3,4} ; Bristol-Myers Squibb ^{1,4} ; Organon Pharmaceuticals Inc. ⁴ ; Forest Pharmaceuticals, Inc. ⁴ ; Cyberonics, Inc. ³ ; Merck & Co., Inc. ³ ; Cypress Bioscience, Inc. ¹ ; Corcept Therapeutics ¹ ; Janssen Pharmaceutica Products, LP ^{1,3} ; Novartis Pharmaceuticals Corporation ¹ ; Shire Ridgewood Pharmaceuticals ¹ ; Somerset Pharmaceuticals Inc. ¹ ; Otsuka America Pharmaceutical, Inc. ¹ | 37 |
| Helen L. Egger, M.D. | Pfizer Inc. ³ | 19 |
| Omar Elhaj, M.D. | AstraZeneca Pharmaceuticals ¹ ; Abbott Laboratories, Inc. ¹ ; Pfizer Inc. ¹ | 25, 67 |
| James M. Ellison, M.D. | GlaxoSmithKline ^{3,4} ; Forest Pharmaceuticals, Inc. ⁴ ; Pfizer Inc. ⁴ ; Wyeth Pharmaceuticals ⁴ ; Bristol-Myers Squibb ⁴ | 75 |

| Presenter | Manufacturer(s) | Program Page # |
|---------------------------|---|----------------|
| Graham J. Emslie, M.D. | Eli Lilly and Company ^{1,3} ; Organon Pharmaceuticals Inc. ³ ; GlaxoSmithKline ¹ ; Forest Pharmaceuticals, Inc. ¹ ; Pfizer Inc. ¹ ; Wyeth Pharmaceuticals ¹ ; Ortho McNeil Pharmaceutical Inc. ⁴ | 42, 66 |
| Mary Jane England, M.D. | American Healthways, Inc. ³ ; US Behavioral Health ⁶ | 43, 83 |
| Milton K. Erman, M.D. | Cephalon Inc. ^{1,6,4,3,5} ; Elan Pharmaceuticals ^{1,3,6} ; King Pharmaceutical ^{1,3,4,6} ; Neurocrine Biosciences Inc. ^{1,3,6} ; Orphan ^{1,3,6} ; Sanofi-Synthelabo Pharmaceuticals, Inc. ^{1,3,6} ; Takeda Pharmaceuticals ^{1,6} ; Janssen Pharmaceutica Products, LP ¹ ; Mallinckrodt, Inc. ^{1,3,6} ; Somaxon Pharmaceuticals ¹ ; Aventis Pharmaceuticals ³ ; Pharmacia ³ ; Pfizer Inc. ^{3,5} ; Res-Med, Inc. ³ ; Merck & Co., Inc. ^{3,5} ; Sepracor Inc. ⁵ ; Forest Pharmaceuticals, Inc. ^{4,5} | 9 |
| Javier I. Escobar, M.D. | Eli Lilly and Company ^{1,4} ; Pfizer Inc. ^{1,4,5} ; Bristol-Myers Squibb ^{1,4,5} ; Otsuka America Pharmaceutical, Inc. ^{1,4} ; Johnson and Johnson PRD ⁵ ; Wyeth Pharmaceuticals ⁴ | 18, 59, 64 |
| Raymond A. Faber, M.D. | Forest Pharmaceuticals, Inc. ⁴ ; Bristol-Myers Squibb ⁴ ; Janssen Pharmaceutica Products, LP ⁴ ; Pfizer Inc. ⁴ | 1 |
| Warachal E. Faison, M.D. | National Institute on Health ³ ; Janssen Pharmaceutica Products, LP ^{3,4} ; Organon Pharmaceuticals Inc. ³ ; Eli Lilly and Company ⁴ ; Pfizer Inc. ⁴ ; Eisai Inc. ⁴ ; Bristol-Myers Squibb ⁴ ; Otsuka America Pharmaceutical ⁴ ; Forest Pharmaceuticals, Inc. ⁴ ; GlaxoSmithKline ^{2,5} | 9, 43, 47 |
| Bruno Falissard, M.D. | Eli Lilly and Company ⁶ | 34 |
| Stephen V. Faraone, Ph.D. | Noven Pharmaceutical ¹ ; Ortho McNeil Pharmaceutical Inc. ^{1,3,4} ; Shire Ridgewood Pharmaceuticals ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; National Institute of Mental Health ³ ; National Institute of Child Health and Human Development ³ ; National Institute of Neurological Diseases and Stroke ³ | 12, 62, 80 |
| Douglas E. Faries, Ph.D. | Eli Lilly and Company ² | 25 |
| Maurizio Fava, M.D. | Lorex Pharmaceuticals ³ ; Lichtwer Pharma GmbH ³ ; Abbott Laboratories, Inc. and Compellis ^{3,6} ; Aspect Medical Systems, Inc. ^{3,6} ; AstraZeneca Pharmaceuticals ^{3,6} ; Bristol-Myers Squibb ^{3,6} ; Cephalon Inc. ^{3,6} ; Eli Lilly and Company ^{3,6} ; Forest Pharmaceuticals, Inc. ^{3,6} ; GlaxoSmithKline ^{3,6} ; Johnson and Johnson PRD ^{3,6} ; Novartis Pharmaceuticals Corporation ^{3,6} ; Organon Pharmaceuticals Inc. ^{3,6} ; Pharmavite ^{3,6} ; Pfizer Inc. ^{3,6} ; Roche Laboratories, a member of the Roche Group ^{3,6} ; Sanofi-Synthelabo Pharmaceuticals, Inc. ^{3,6} ; Solvay Pharmaceuticals, Inc. ^{3,6} ; Wyeth Pharmaceuticals ^{3,6} ; Bayer AG Corporation, Pharmaceutical Division ⁶ ; Janssen Pharmaceutica Products, LP ⁶ ; Knoll Pharmaceuticals ⁶ ; Lundbeck ⁶ ; Cypress Bioscience, Inc. ⁶ ; Somerset Pharmaceuticals Inc. ⁶ | 4, 55, 89 |
| Francisco Fernandez, M.D. | Wyeth Pharmaceuticals ^{1,4} ; Forest Pharmaceuticals, Inc. ^{1,4} ; Pfizer Inc. ^{1,4} ; Eli Lilly and Company ⁴ | 20, 43, 51 |
| Robert L. Findling, M.D. | Abbott Laboratories, Inc. ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Best Practices ¹ ; Bristol-Myers Squibb ^{1,3,4} ; Celltech-Medeva ^{1,3} ; Forest Pharmaceuticals, Inc. ^{1,3} ; GlaxoSmithKline ^{1,3,4} ; Johnson and Johnson PRD ^{1,3,4} ; Layton Biosciences, Inc. ³ ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; Nature's Herbs ³ ; Novartis Pharmaceuticals Corporation ^{1,3} ; Noven Pharmaceutical ¹ ; Organon Pharmaceuticals Inc. ³ ; Otsuka America Pharmaceutical ^{1,3,4} ; PharmaStar, LLC ¹ ; Pharmaceutical Product Development, Inc. (PPD) ¹ ; Pfizer Inc. ^{1,3} ; Shire Ridgewood Pharmaceuticals ^{1,3,4} ; Solvay Pharmaceuticals, Inc. ³ ; Somerset Pharmaceuticals Inc. ^{1,3} ; Wyeth Pharmaceuticals ^{1,3,4} | 2, 25 |
| Naomi Fineberg, M.A. | AstraZeneca Pharmaceuticals ³ ; Janssen Pharmaceutica Products, LP ³ ; Lundbeck ¹ | 79 |
| David A. Fishbain, M.D. | Eli Lilly and Company ¹ | 4 |
| Sebern F. Fisher, M.A. | EEG Spectrum International ^{1,4,5} | 74 |
| James N. Flack, M.D. | Janssen Pharmaceutica Products, LP ⁴ | 19 |
| Lois T. Flaherty, M.D. | Merck & Co., Inc. ^{6,5} ; Pfizer Inc. ⁵ | 20, 85 |
| Marshal Folstein, M.D. | CNS Vital Signs LLC | 68 |
| Brent P. Forester, M.D. | Eli Lilly and Company ^{3,4} ; Wyeth Pharmaceuticals ⁴ ; Novartis Pharmaceuticals Corporation ⁴ ; Janssen Pharmaceutica Products, LP ⁴ ; Abbott Laboratories, Inc. ^{3,4} ; AstraZeneca Pharmaceuticals ⁴ ; Pfizer Inc. ^{3,4} | 75 |
| Paul T. Francis, Ph.D. | Pfizer Inc./Eisai Inc. ⁴ ; Lundbeck ⁴ ; Forest Pharmaceuticals, Inc. ⁴ | 9 |
| Ellen Frank, Ph.D. | Pfizer Inc. ¹ ; Pfizer Italiana ¹ ; Eli Lilly and Company ¹ ; Forest Pharmaceuticals, Inc. ³ | 4 |
| Robert Freedman, M.D. | Abbott Laboratories, Inc. ³ ; The Dept. of Veteran Affairs ⁶ | 41 |
| Matthew Friedman, M.D. | Shire Ridgewood Pharmaceuticals ¹ ; GlaxoSmithKline ⁴ ; Ortho McNeil Pharmaceutical Inc. ⁴ ; AstraZeneca Pharmaceuticals ⁴ | 19, 34, 95 |
| Lara R. Fuchs, M.D. | GlaxoSmithKline ⁶ | 66 |
| Manuel Garcia, M.D. | Pfizer Inc. ^{2,5} | 45 |
| Bradley N. Gaynes, M.D. | Pfizer Inc. ¹ | 58 |
| Oswaldo Gaytan, Jr., M.D. | Pfizer Inc. ⁴ ; AstraZeneca Pharmaceuticals ⁴ ; Janssen Pharmaceutica Products, LP ⁴ | 79 |

DISCLOSURE INDEX

| Presenter | Manufacturer(s) | Program Page # |
|-------------------------------|--|------------------------|
| Alan J. Gelenberg, M.D. | Pfizer Inc. ^{1,3,4} ; Wyeth Pharmaceuticals ^{1,3,4} ; Cyberonics, Inc. ^{1,4} ; Eli Lilly and Company ¹ ; Vela Pharmaceuticals ¹ ; Best Practice ¹ ; Bristol-Myers Squibb ¹ ; AstraZeneca Pharmaceuticals ¹ ; GlaxoSmithKline ¹ ; Roche Laboratories, a member of the Roche Group ¹ ; ZARS ¹ ; Express Scripts ¹ | 22 |
| Mark S. George, M.D. | Neotonus, Inc. (now Neuronetics Inc.) ^{1,3} ; Janssen Pharmaceutica Products, LP ^{3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{3,4} ; GlaxoSmithKline ^{3,4} ; Solvay/Duphar ^{3,4} ; Parke Davis ^{3,4} ; Cortex Pharmaceuticals ³ ; Aventis Pharmaceuticals ¹ ; DarPharma, Inc. ³ ; Picker International (now Phillips) ^{3,4} ; Dantee (Medtronic) ³ ; Cyberonics, Inc. ^{1,3,4} ; Dupont Pharma ³ ; Medipysics/Amersham ^{3,4} ; Cephos Corp. ^{1,3} | 6, 15, 47 |
| Anna M. Georgiopoulos, M.D. | GlaxoSmithKline ³ | 82 |
| S. Nassir Ghaemi, M.D. | Janssen Pharmaceutica Products, LP ^{1,3,6} ; AstraZeneca Pharmaceuticals ^{1,3,6} ; Novartis Pharmaceuticals Corporation ³ ; Abbott Laboratories, Inc. ^{3,6} ; Elan Pharmaceuticals ³ ; GlaxoSmithKline ^{1,6} ; Forest Pharmaceuticals, Inc. ⁶ ; Eli Lilly and Company ⁶ | 33, 36, 56, 77 |
| Leslie H. Gise, M.D. | Medco Health ¹ | 14, 30 |
| Alexander H. Glassman, M.D. | Pfizer Inc. ^{1,4} ; GlaxoSmithKline ^{1,4} ; Eli Lilly and Company ¹ ; AstraZeneca Pharmaceuticals ^{1,4} ; Ono Pharma ¹ | 20 |
| Ira D. Glick, M.D. | Janssen Pharmaceutica Products, LP ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} | 15, 33, 59, 82 |
| Donald C. Goff, M.D. | Cortex Pharmaceuticals ³ ; Eli Lilly and Company ^{1,6} ; Janssen Pharmaceutica Products, LP ^{1,3,6} ; AstraZeneca Pharmaceuticals ^{1,6} ; Pfizer Inc. ^{1,6} ; Bristol-Myers Squibb ^{1,6} ; Cephalon Inc. ³ ; GlaxoSmithKline ³ ; Organon Pharmaceuticals Inc. ³ | 7 |
| Robert M. Goisman, M.D. | Bristol-Myers Squibb ¹ ; AstraZeneca Pharmaceuticals ⁴ ; Pfizer Inc. ⁴ | 64 |
| Joseph F. Goldberg, M.D. | Abbott Laboratories, Inc. ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Johnson and Johnson PRD ¹ ; Novartis Pharmaceuticals Corporation ¹ ; Ortho McNeil Pharmaceutical Inc. ¹ ; Organon Pharmaceuticals Inc. ¹ ; Pfizer Inc. ^{1,4} ; UCB Pharmaceuticals ¹ | 23, 77 |
| Robert N. Golden, M.D. | Bristol-Myers Squibb ¹ ; Duke Clinical Research Institute (DCRI) ¹ ; Forest Pharmaceuticals, Inc. ³ ; GlaxoSmithKline ¹ ; Janssen Pharmaceutica Products, LP ¹ ; National Institute of Mental Health ³ ; Organon Pharmaceuticals Inc. ^{3,4} ; Ovation Pharmaceuticals ¹ ; Pfizer Inc. ^{1,3} ; Wyeth Pharmaceuticals ¹ | 69 |
| Stephen M. Goldfinger, M.D. | Bristol-Myers Squibb ¹ ; Mallinckrodt Pharmaceuticals ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,4,5} ; IVAX Pharmaceuticals, Inc. ^{1,4,5} | 45, 68, 74, 92 |
| Morris B. Goldman, M.D. | Bristol-Myers Squibb ¹ | 27 |
| Andres Gomez-Caminero, Ph.D. | GlaxoSmithKline ⁵ ; Bristol-Myers Squibb ² | 54 |
| Karl Goodkin, M.D. | GlaxoSmithKline ³ ; Merck & Co., Inc. ^{1,4} ; BI ^{1,4} ; Advance ImmvriT, Inc. ⁶ ; American Society for Microbiology ⁶ | 43 |
| David Goodman, M.D. | Forest Pharmaceuticals, Inc. ^{1,3,4} ; Shire Ridgewood Pharmaceuticals ^{1,3,4} ; Ortho McNeil Pharmaceutical Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,4} ; Pfizer Inc. ⁵ ; Eli Lilly and Company ⁴ ; Wyeth Pharmaceuticals ⁴ | 32 |
| Marianne Goodman, M.D. | Forest Pharmaceuticals, Inc. ³ | 33 |
| Frederick K. Goodwin, M.D. | Solvay Pharmaceuticals, Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; Abbott Laboratories, Inc. ³ ; Forest Pharmaceuticals, Inc. ³ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ³ ; Janssen Pharmaceutica Products, LP ^{3,4} | 36, 56 |
| Kevin F. Gray, M.D. | Novartis Pharmaceuticals Corporation ^{4,1} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{4,1} ; Pfizer Inc. ^{4,1} ; Janssen Pharmaceutica Products, LP ⁴ ; Bristol-Myers Squibb ^{4,1} | 1 |
| John F. Greden, M.D. | Eli Lilly and Company ¹ ; Wyeth Pharmaceuticals ¹ ; Merck & Co., Inc. ¹ ; Cyberonics, Inc. ¹ ; Neurocrine Biosciences Inc. ¹ ; GlaxoSmithKline ¹ | 11, 20, 37, 41, 49, 84 |
| Alan I. Green, M.D. | Bristol-Myers Squibb ^{1,3,4} ; Otsuka America Pharmaceutical, Inc. ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Forest Pharmaceuticals, Inc. ^{1,3} ; Novartis Pharmaceuticals Corporation ³ | 29, 36, 50 |
| Melva I. Green, M.D. | Pfizer Inc. ⁴ | 43 |
| Benjamin D. Greenberg, M.D. | Medtronic, Inc. ^{3,4} ; Aspect Medical Systems, Inc. ¹ | 6, 90 |
| Laurence L. Greenhill, M.D. | Novartis Pharmaceuticals Corporation ^{3,1} ; Eli Lilly and Company ^{1,3,4} ; Celltech Pharmaceuticals, Ltd. ^{1,4} ; Ortho McNeil Pharmaceutical Inc. ¹ ; Janssen Pharmaceutica Products, LP ¹ | 23 |
| Carl B. Greiner, M.D. | Janssen Pharmaceutica Products, LP ⁴ | 43, 64 |
| Dimitri E. Grigoriadis, Ph.D. | Neurocrine Biosciences Inc. ² | 32 |

| Presenter | Manufacturer(s) | Program Page # |
|------------------------------|--|-------------------|
| George T. Grossberg, M.D. | Abbott Laboratories, Inc. ^{1,3} ; Bristol-Myers Squibb ^{1,3} ; Forest Pharmaceuticals, Inc. ^{1,3} ; Pfizer Inc. ³ ; Janssen Pharmaceutica Products, LP ¹ ; AstraZeneca Pharmaceuticals ^{1,3} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3} ; Organon Pharmaceuticals Inc. ^{1,3} ; Omnicare, Inc. ³ ; Wellcome ³ ; Eunoe, Inc. ³ ; Boehringer-Ingelheim Pharmaceuticals ³ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ¹ ; Novartis Pharmaceuticals Corporation ^{1,3} | 9, 13 |
| Raquel E. Gur, M.D. | Pfizer Inc. ¹ ; AstraZeneca Pharmaceuticals ³ | 30 |
| Robert E. Hales, M.D. | Bristol-Myers Squibb ^{1,4} | 13, 24, 39 |
| Thomas E. Hansen, M.D. | AstraZeneca Pharmaceuticals ^{1,4} ; Pfizer Inc. ^{1,4} ; Bristol-Myers Squibb ^{1,4} ; Eli Lilly and Company ^{1,4} | 19 |
| Cynthia L. Harden, M.D. | Pfizer Inc. ³ ; AstraZeneca Pharmaceuticals ³ ; GlaxoSmithKline ^{1,3,4} ; UCB Pharmaceuticals ^{1,4} ; Novartis Pharmaceuticals Corporation ⁴ | 95 |
| Patrice A. Harris, M.D. | Eli Lilly and Company ^{1,4} ; Pfizer Inc. ¹ | 85 |
| David G. Harrison, M.D. | CV Therapeutics ⁶ ; AG1 ^{1,5} ; Novartis ¹ | 42 |
| Philip D. Harvey, Ph.D. | Janssen Pharmaceutica Products, LP ¹ ; Aventis Pharmaceuticals ¹ ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; Pfizer Inc. ^{1,4} ; Novartis Pharmaceuticals Corporation ¹ ; Bristol-Myers Squibb ^{1,3,4} | 12 |
| Daniel W. Haupt, M.D. | Janssen Pharmaceutica Products, LP ³ ; Abbott Laboratories, Inc. ^{1,3,4} ; Pfizer Inc. ³ ; Bristol-Myers Squibb ^{1,3,4} ; AstraZeneca Pharmaceuticals ⁴ | 7 |
| David T. Healy, M.D. | AstraZeneca Pharmaceuticals ^{1,4} ; Vickery and Waldner, Baum Hedlund ⁶ | 56 |
| David C. Henderson, M.D. | Janssen Pharmaceutica Products, LP ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Pfizer Inc. ^{1,3,4} | 1, 32, 56 |
| Paula L. Hensley, M.D. | Forest Pharmaceuticals, Inc. ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,4} ; Eli Lilly and Company ³ ; Hoffman La Roche Ltd. ³ | 31 |
| Barry Herman, M.D. | Pfizer Inc. ² | 45 |
| Alan R. Hirsch, M.D. | Ayerst ⁴ ; GlaxoSmithKline ³ ; Eli Lilly and Company ⁴ ; UpJohn ⁴ ; Ciba-Geigy ⁴ ; Johnson and Johnson PRD ¹ ; Parke Davis ⁴ ; Abbott Laboratories, Inc. ⁴ ; Proctor & Gamble ¹ ; Pharmacia ³ | 87 |
| Robert M.A. Hirschfeld, M.D. | Wyeth Pharmaceuticals ^{1,3} ; Abbott Laboratories, Inc. ³ ; AstraZeneca Pharmaceuticals ³ ; Bristol-Myers Squibb ³ ; Forest Pharmaceuticals, Inc. ³ ; GlaxoSmithKline ³ ; Janssen Pharmaceutica Products, LP ³ ; Eli Lilly and Company ³ ; Novartis Pharmaceuticals Corporation ³ ; Organon Pharmaceuticals Inc. ³ ; Pfizer Inc. ³ ; Shire Ridgewood Pharmaceuticals ³ ; UCB Pharmaceuticals ³ | 77 |
| Max Hirshkowitz, Ph.D. | Cephalon Inc. ^{3,4} ; Sanofi-Synthelabo Pharmaceuticals, Inc. ^{3,4} ; Aventis Pharmaceuticals ³ ; Pfizer Inc. ³ ; Merck & Co., Inc. ³ ; Orphan ³ ; Takeda Pharmaceuticals ³ ; NBI, Inc. ³ | 40 |
| Eric Hollander, M.D. | Lilly Research Laboratories, a division of Eli Lilly and Company ³ ; Janssen Pharmaceutica Products, LP ³ ; Ortho McNeil Pharmaceutical Inc. ^{1,3} ; Pfizer Inc. ^{3,1} ; Wyeth Pharmaceuticals ^{1,3} ; Solvay Pharmaceuticals, Inc. ¹ ; UCB Pharmaceuticals ³ ; Abbott Laboratories, Inc. ^{1,3} | 3, 33, 61, 79, 98 |
| Robert C. Hsiung, M.D. | W.W. Norton & Company ⁶ | 40, 63 |
| Rona Hu, M.D. | AstraZeneca Pharmaceuticals ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; Forest Pharmaceuticals, Inc. ³ ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Abbott Laboratories, Inc. ¹ ; Eli Lilly and Company ^{1,4} ; Pfizer Inc. ^{1,4} ; GlaxoSmithKline ⁴ ; Cephalon Inc. ⁴ | 11 |
| James I. Hudson, M.D. | Eli Lilly and Company ^{1,3} ; Ortho McNeil Pharmaceutical Inc. ^{1,3} | 6 |
| Dan V. Iosifescu, M.D. | Pfizer Inc. ¹ ; Aspect Medical Systems, Inc. ³ ; Janssen Pharmaceutica Products, LP ³ ; Forest Pharmaceuticals, Inc. ³ ; Eli Lilly and Company ⁴ | 48 |
| Waguih W. Ishak, M.D. | Pfizer Inc. ¹ ; AstraZeneca Pharmaceuticals ¹ ; Eli Lilly and Company ¹ ; Bristol-Myers Squibb ¹ | 69, 73, 75 |
| Saleem Ismail, M.D. | National Institute of Mental Health ³ ; Janssen Pharmaceutica Products, LP ⁴ ; AstraZeneca Pharmaceuticals ⁴ ; Forest Pharmaceuticals, Inc. ^{3,4} | 77 |
| Jeanne Jackson-Siegel, M.D. | Abbott Laboratories, Inc. ⁴ ; Janssen Pharmaceutica Products, LP ⁴ ; Eli Lilly and Company ⁴ ; Pfizer Inc. ⁴ ; Organon Pharmaceuticals Inc. ⁴ ; Novartis Pharmaceuticals Corporation ⁴ ; Forest Pharmaceuticals, Inc. ⁴ ; AstraZeneca Pharmaceuticals ⁴ | 39 |
| Kay Redfield Jamison, Ph.D. | GlaxoSmithKline ⁴ ; Eli Lilly and Company ⁴ ; AstraZeneca Pharmaceuticals ⁴ | 36 |
| Philip G. Janicak, M.D. | Pfizer Inc. ^{1,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Abbott Laboratories, Inc. ⁴ ; Neurocrine Biosciences Inc. ³ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ³ | 27 |
| Geetha Jayaram, M.D. | Pfizer Inc. ⁴ ; GlaxoSmithKline ⁴ ; Cephalon Inc. ⁴ ; Janssen Pharmaceutica Products, LP ⁴ | 23, 43, 52, 75 |
| Dilip V. Jeste, M.D. | Bristol-Myers Squibb ^{1,3} ; Eli Lilly and Company ^{1,3} ; AstraZeneca Pharmaceuticals ^{1,3} ; Pfizer Inc. ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,2,3,4,5} | 30, 77 |
| Wei Jiang, M.D. | Pfizer Inc. ^{3,4} | 81 |
| Hadine Joffe, M.D. | Abbott Laboratories, Inc. ³ ; Eli Lilly and Company ⁴ ; Berlex Laboratories, Inc. ⁶ ; Wyeth Pharmaceuticals ⁶ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ⁶ | 3, 9 |

DISCLOSURE INDEX

| Presenter | Manufacturer(s) | Program Page # |
|---------------------------|--|-----------------------|
| Bankole A. Johnson, M.D. | Ortho McNeil Pharmaceutical Inc. ^{1,4} ; Forest Pharmaceuticals, Inc. ⁴ | 31, 56 |
| Jeffrey P. Kahn, M.D. | Work Psych Association, Inc. ⁶ | 72 |
| Amir H. Kalali, M.D. | AstraZeneca Pharmaceuticals ^{1,4,6} ; Eli Lilly and Company ^{1,4,6} ; Janssen Pharmaceutica Products, LP ^{1,4,6} ; Shire Ridgewood Pharmaceuticals ^{1,4,6} ; Bristol-Myers Squibb ^{1,6} ; Elan Pharmaceuticals ^{1,6} ; GlaxoSmithKline ^{1,6} ; Neurocrine Biosciences Inc. ^{1,6} ; Abbott Laboratories, Inc. ⁴ ; Forest Pharmaceuticals, Inc. ⁴ ; Novartis Pharmaceuticals Corporation ⁴ ; Organon Pharmaceuticals Inc. ⁴ ; Pfizer Inc. ⁴ ; Wyeth Pharmaceuticals ⁴ ; GlaxoSmithKline ⁴ | 56 |
| Ned H. Kalin, M.D. | National Institute of Health ³ ; Dana Foundation ³ ; Stanley Foundation ³ ; Wyeth Pharmaceuticals ^{3,4} ; Janssen Pharmaceutica Products, LP ^{1,4} ; GlaxoSmithKline ¹ ; Neuroscience Advisory Board ¹ ; Neurocrine Biosciences Inc. ¹ ; Novartis Pharmaceuticals Corporation ¹ ; Bristol-Myers Squibb ¹ ; Somerset Pharmaceuticals Inc. ¹ ; Corcept Therapeutics ¹ ; Cypress Bioscience, Inc. ¹ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ¹ ; Otsuka America Pharmaceutical ¹ ; Eli Lilly and Company ¹ ; Petent Pharmaceuticals ¹ ; Tularik ¹ ; Neuronetics ¹ ; Neurocrine Biosciences Inc. ⁵ ; Promoter Neurosciences, LLC. ² ; Pfizer Inc. ⁵ | 9 |
| Eric R. Kandel, M.D. | Memory Pharmaceuticals ⁶ | 16 |
| John M. Kane, M.D. | Abbott Laboratories, Inc. ^{1,4} ; AstraZeneca Pharmaceuticals ^{1,4} ; Bristol-Myers Squibb ^{1,4} ; Novartis Pharmaceuticals Corporation ^{1,4} ; Janssen Pharmaceutica Products, LP ^{1,4} ; Eli Lilly and Company ^{1,4} ; Pfizer Inc. ⁴ | 10, 82 |
| Shitij Kapur, M.D. | AstraZeneca Pharmaceuticals ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Neuromolecular Inc. ³ ; Pfizer Inc. ^{1,3,4} ; Wyeth Pharmaceuticals ^{1,3,4} ; Bristol-Myers Squibb ^{1,4} ; GlaxoSmithKline ^{1,4} ; Solvay Pharmaceuticals, Inc. ¹ | 12, 80 |
| Jordan F. Karp, M.D. | AstraZeneca Pharmaceuticals ⁴ ; Pfizer Inc. ⁴ | 94 |
| Ira R. Katz, M.D. | AstraZeneca Pharmaceuticals ^{1,6} ; Eli Lilly and Company ^{1,6} ; Pfizer Inc. ^{1,6} ; Janssen Pharmaceutica Products, LP ^{1,6} | 23 |
| Nathaniel P. Katz, M.D. | Alza/Ortho McNeil Pharmaceutical Inc. ¹ ; Biovail Laboratories, Inc. ¹ ; Forest Pharmaceuticals, Inc. ¹ ; GlaxoSmithKline ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Merck & Co., Inc. ¹ ; Ortho McNeil Pharmaceutical Inc. ¹ ; Purdue Pharma L.P. ¹ ; Cephalon Inc. ¹ | 60 |
| David J. Katzelnick, M.D. | Healthcare Technology Systems, Inc. ⁶ | 84 |
| Jerald Kay, M.D. | AstraZeneca Pharmaceuticals ⁴ ; Pfizer Inc. ⁴ | 68, 79 |
| Paul E. Keck, Jr., M.D. | Corcept Therapeutics ¹ ; Novartis Pharmaceuticals Corporation ¹ ; Shire Ridgewood Pharmaceuticals ¹ ; Wyeth Pharmaceuticals ¹ ; Abbott Laboratories, Inc. ^{1,3} ; AstraZeneca Pharmaceuticals ^{1,3} ; Bristol-Myers Squibb ^{1,3} ; GlaxoSmithKline ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3} ; Eli Lilly and Company ^{1,3} ; Ortho McNeil Pharmaceutical Inc. ^{1,3} ; Pfizer Inc. ^{1,3} ; UCB Pharmaceuticals ^{1,3} ; American Diabetes Association ³ ; Merck & Co., Inc. ³ ; National Institute of Mental Health ³ ; National Institute of Drug Abuse (NIDA) ³ ; Organon Pharmaceuticals Inc. ³ ; Stanley Medical Research Institute (SMRI) ³ | 3, 4, 39 |
| Richard S.E. Keefe, Ph.D. | Eli Lilly and Company ^{1,3,4} ; Johnson and Johnson PRD ^{1,3,4} ; Pfizer Inc. ¹ ; AstraZeneca Pharmaceuticals ³ ; GlaxoSmithKline ¹ ; Abbott Laboratories, Inc. ¹ ; Organon Pharmaceuticals Inc. ¹ ; Aventis Pharmaceuticals ¹ ; Lundbeck ¹ ; Solvay Pharmaceuticals, Inc. ¹ ; Wyeth Pharmaceuticals ¹ ; Repligen ¹ ; Bristol-Myers Squibb ¹ ; Forest Pharmaceuticals, Inc. ¹ | 4 |
| Martin B. Keller, M.D. | Bristol-Myers Squibb ¹ ; Collegium ¹ ; Cypress Bioscience, Inc. ¹ ; Abbott Laboratories, Inc. ¹ ; Cyberonics, Inc. ¹ ; Cephalon Inc. ¹ ; Eli Lilly and Company ^{1,3} ; Forest Pharmaceuticals, Inc. ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3} ; Merck & Co., Inc. ^{1,3} ; Organon Pharmaceuticals Inc. ^{1,3} ; Otsuka America Pharmaceutical ¹ ; Pfizer Inc. ^{1,3} ; Pharmacia ¹ ; Pharmastar ¹ ; Sepracor Inc. ¹ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ¹ ; Wyeth Pharmaceuticals ^{1,3} ; Somerset Pharmaceuticals Inc. ¹ ; Vela Pharmaceuticals ¹ ; Scirex ¹ | 2, 11 |
| Charles H. Kellner, M.D. | Somatics, LLC ⁶ | 26 |
| Douglas K. Kelsey, M.D. | Eli Lilly and Company ² | 34 |
| Sidney H. Kennedy, M.D. | Eli Lilly and Company ¹ ; Pfizer Inc. ¹ ; Organon Pharmaceuticals Inc. ¹ ; AstraZeneca Pharmaceuticals ^{1,3} ; GlaxoSmithKline ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3} ; Lundbeck ^{1,3,4} ; Wyeth Pharmaceuticals ⁴ ; Biovail Laboratories, Inc. ^{1,4} ; Merck & Co., Inc. ^{3,4} ; Boehringer-Ingelheim ^{1,4} ; Ortho McNeil Pharmaceutical Inc. ^{3,4} ; Servier ⁴ ; Janssen Pharmaceutica Products, LP ^{3,4} | 32 |
| Justine M. Kent, M.D. | Pfizer Inc. ¹ | 6 |
| Terence A. Ketter, M.D. | Cephalon Inc. ¹ ; Pfizer Inc. ^{1,4} ; Abbott Laboratories, Inc. ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; Elan Pharmaceuticals ^{1,3} ; Eli Lilly and Company ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Novartis Pharmaceuticals Corporation ^{1,3,4} ; Shire Ridgewood Pharmaceuticals ^{1,3} | 13, 36, 76 |
| Bryan H. King, M.D. | Janssen Pharmaceutica Products, LP ⁴ | 66 |

| Presenter | Manufacturer(s) | Program Page # |
|---------------------------------|--|----------------|
| David G. Kingdon, M.D. | Eli Lilly and Company ⁶ ; Bristol-Myers Squibb ⁶ ; AstraZeneca Pharmaceuticals ⁶ ; GlaxoSmithKline ⁶ ; Novartis Pharmaceuticals Corporation ⁶ ; Janssen Pharmaceutica Products, LP ⁶ ; Pfizer Inc. ⁶ | 8, 92 |
| Joel I. Kirson, M.D. | GlaxoSmithKline ⁴ | 23, 71 |
| Herbert D. Kleber, M.D. | Reckitt Benckiser Pharmaceuticals ³ ; Purdue Pharma L.P. ¹ | 15, 60, 80 |
| Scott Kollins, Ph.D. | Ortho McNeil Pharmaceutical Inc. ^{1,4} ; Shire Ridgewood Pharmaceuticals ^{1,3} ; Celltech Pharmaceuticals, Ltd. ³ ; Lilly Research Laboratories, a division of Eli Lilly and Company ³ | 11 |
| George F. Koob, Ph.D. | Merck & Co., Inc./Lipha ¹ ; Titan Pharmaceuticals ¹ ; Addex Pharmaceuticals ¹ ; Forest Pharmaceuticals, Inc. ¹ | 56, 62, 96 |
| Lorin M. Koran, M.D. | Forest Pharmaceuticals, Inc. ^{3,4} ; Pfizer Inc. ^{3,4} ; AstraZeneca Pharmaceuticals ³ ; GlaxoSmithKline ³ | 79 |
| Susan G. Kornstein, M.D. | Pfizer Inc. ^{1,3} ; Bristol-Myers Squibb ^{1,3} ; Eli Lilly and Company ^{1,3} ; Merck & Co., Inc. ³ ; Forest Pharmaceuticals, Inc. ³ ; Wyeth Pharmaceuticals ^{3,1} ; Berlex Laboratories, Inc. ³ ; Sepracor Inc. ³ ; Novartis Pharmaceuticals Corporation ³ ; Warner-Chilcott ¹ ; Biovail Laboratories Inc. ³ | 13, 39, 66 |
| Diana M. Koziupa, M.D. | Eli Lilly and Company ^{3,4} ; Bristol-Myers Squibb ^{1,4} ; Otsuka America Pharmaceutical ⁴ ; Forest Pharmaceuticals, Inc. ⁴ ; GlaxoSmithKline ⁴ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ⁴ ; Wyeth Pharmaceuticals ⁴ | 60 |
| Henry R. Kranzler, M.A. | Alkermes Pharmaceuticals ¹ ; Forest Pharmaceuticals, Inc. ¹ ; Bristol-Myers Squibb ¹ ; Ortho McNeil Pharmaceutical Inc. ³ ; Drug Abuse Sciences ⁴ | 31 |
| Christopher J. Kratochvil, M.D. | Eli Lilly and Company ^{1,3,4} ; Forest Pharmaceuticals, Inc. ³ ; Cephalon Inc. ³ ; GlaxoSmithKline ³ ; Ortho McNeil Pharmaceutical Inc. ^{3,4} | 34, 62 |
| John E. Kraus, Jr., M.D. | Bristol-Myers Squibb ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} | 4 |
| K. Ranga R. Krishnan, M.D. | GlaxoSmithKline ¹ ; Pfizer Inc. ¹ ; Eli Lilly and Company ¹ ; Vela Pharmaceuticals ¹ ; Lundbeck ¹ ; Abbott Laboratories, Inc. ¹ ; Amgen ¹ ; Johnson and Johnson PRD ¹ ; Merck & Co., Inc. ¹ ; NPS Pharmaceuticals ¹ ; Organon Pharmaceuticals Inc. ¹ ; Otsuka America Pharmaceutical ¹ ; Pfizer Inc. ¹ ; Somerset Pharmaceuticals Inc. ¹ ; Wyeth Pharmaceuticals ¹ ; Synaptic ¹ | 2, 41, 62, 81 |
| Kurt Kroenke, M.D. | AstraZeneca Pharmaceuticals ¹ ; Wyeth Pharmaceuticals ^{1,3} ; Eli Lilly and Company ^{1,3} ; Pfizer Inc. ^{1,3} | 25 |
| Larry A. Kroutil, M.P.H. | Eli Lilly and Company ³ | 90 |
| John H. Krystal, M.D. | Organon Pharmaceuticals Inc. ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Aventis Pharmaceuticals ¹ ; GlaxoSmithKline ¹ ; Pfizer Inc. ¹ ; Eli Lilly and Company ¹ ; Forest Pharmaceuticals, Inc. ¹ ; Takeda Pharmaceuticals ¹ ; Merz Pharmaceuticals ¹ ; Centre de Recherche Pierre Fabre ¹ ; UCB Pharmaceuticals ¹ ; Sumitomo Pharmaceuticals America, Ltd. ¹ | 11, 29 |
| Elisabeth J.S. Kunkel, M.D. | Pfizer Inc. ⁴ ; Intramed ⁴ ; Forest Pharmaceuticals, Inc. ⁴ ; Wyeth Pharmaceuticals ⁴ | 40, 91, 96 |
| David J. Kupfer, M.D. | Pfizer Inc. ¹ ; Eli Lilly and Company ¹ ; Forest Pharmaceuticals, Inc. ¹ ; F. Hoffmann-La Roche, LTD. ¹ ; Servier Amerique ¹ | 9, 20, 30 |
| Raymond W. Lam, M.D. | Biovail Laboratories Inc. ⁴ ; Canadian Network for Mood and Anxiety Treatments ⁴ ; Eli Lilly and Company ^{3,4} ; GlaxoSmithKline ^{3,4} ; Litebook Company, Inc. ⁴ ; Lundbeck ^{3,4} ; Shire Ridgewood Pharmaceuticals ⁴ ; Wyeth Pharmaceuticals ^{3,4} ; AstraZeneca Pharmaceuticals ³ ; Canadian Institutes of Health Research ³ ; Janssen Pharmaceutica Products, LP ³ ; Merck & Co., Inc. ³ ; Roche Laboratories, a member of the Roche Group ³ ; Servier Canada ³ ; Vancouver Hospital Foundation ³ | 61 |
| Jeanne Landgraf, M.A. | Shire Ridgewood Pharmaceuticals ³ | 32 |
| Edward C. Lauterbach, M.D. | Bristol-Myers Squibb ³ ; Forest Pharmaceuticals, Inc. ⁴ | 5, 48, 71, 89 |
| Helen Lavretsky, M.D. | Forest Pharmaceuticals, Inc. ^{3,4,1} ; Janssen Pharmaceutica Products, LP ^{4,1} ; Pfizer Inc. ⁴ ; AstraZeneca Pharmaceuticals ^{1,3} ; Bristol-Myers Squibb ^{1,3} | 62, 64 |
| William Lawson, M.D. | Abbott Laboratories, Inc. ^{3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{3,4} ; Pfizer Inc. ^{3,4} | 25, 56 |
| Arthur L. Lazarus, M.D. | AstraZeneca Pharmaceuticals ^{2,5} | 22 |
| Eric J. Lenze, M.D. | Forest Pharmaceuticals, Inc. ³ ; Janssen Pharmaceutica Products, LP ³ | 6 |
| Stefan M. Leucht, M.D. | Johnson and Johnson PRD ^{1,4} ; Eli Lilly and Company ⁴ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ^{3,4} | 10 |
| Alan I. Levenson, M.D. | Pyschiatrists' Purchasing Group. Inc. ⁶ | 19 |
| James L. Levenson, M.D. | Eli Lilly and Company ¹ | 40, 67, 91 |
| Frances R. Levin, M.D. | Eli Lilly and Company ¹ ; Ortho McNeil Pharmaceutical Inc. ³ ; UCB Pharmaceuticals ^{1,3} | 50, 81 |
| Ronald W. Levin, M.D. | Pfizer Inc. ⁵ ; Amgen ⁵ ; Cezaene ⁵ ; Icos ⁵ | 78 |

DISCLOSURE INDEX

| Presenter | Manufacturer(s) | Program Page # |
|-------------------------------|--|-----------------------|
| Jeffrey A. Lieberman, M.D. | Abbott Laboratories, Inc. ¹ ; AstraZeneca Pharmaceuticals ^{1,3} ; Aventis Pharmaceuticals ¹ ; Bristol-Myers Squibb ^{1,3} ; Cyberonics, Inc. ⁵ ; Cypress Bioscience, Inc. ⁵ ; Eli Lilly and Company ^{1,3} ; GlaxoSmithKline ^{1,3} ; Janssen Pharmaceutica Products, LP ³ ; Novartis Pharmaceuticals Corporation ^{1,3} ; Organon Pharmaceuticals Inc. ^{1,3} ; Pfizer Inc. ¹ ; Solvay Pharmaceuticals, Inc. ¹ | 4, 12, 31, 51 |
| Michael R. Liebowitz, M.D. | Forest Pharmaceuticals, Inc. ¹ ; Pfizer Inc. ^{1,3,4} ; Wyeth Pharmaceuticals ^{1,3,4} ; Roche Laboratories, a member of the Roche Group ¹ ; Solvay Pharmaceuticals, Inc. ¹ ; Eli Lilly and Company ¹ ; GlaxoSmithKline ^{1,3} | 3, 6 |
| Kevin O. Lim | Eli Lilly and Company ^{1,3} ; Avertis ¹ | 80 |
| Jean-Pierre Lindenmayer, M.D. | Novartis Pharmaceuticals Corporation ¹ ; Eli Lilly and Company ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,4} ; Bristol-Myers Squibb ⁴ ; Pfizer Inc. ³ ; AstraZeneca Pharmaceuticals ³ | 68 |
| Marsha Lineham, Ph.D. | Eli Lilly and Company ³ | 7 |
| Sarah H. Lisanby, M.D. | National Institute of Mental Health ³ ; National Alliance for Research in Schizophrenia and Depression ³ ; Stanley Foundation ³ ; American Federation for Aging Research (AFAR) ³ ; The Defense Advances Research Project Agency (DARPA) ³ ; Magstim Company ³ ; Cyberonics, Inc. ⁴ | 6, 37, 47, 51, 69 |
| Sheila M. Loboprabhu, M.D. | AstraZeneca Pharmaceuticals ⁴ | 25, 45 |
| Eric B. London, M.D. | Wyeth Pharmaceuticals ⁴ ; Pfizer Inc. ⁴ ; GlaxoSmithKline ⁴ ; Eli Lilly and Company ⁴ ; Cephalon Inc. ⁴ | 61 |
| Shari I. Lusskin, M.D. | Wyeth Pharmaceuticals ⁴ ; AstraZeneca Pharmaceuticals ⁴ ; Pfizer Inc. ⁴ ; GlaxoSmithKline ⁴ | 63 |
| R. Bruce Lydiard, M.D. | Pfizer Inc. ¹ | 9 |
| Contantine Lyketosos, M.D. | Eisai ^{1,4} ; Forest Laboratories ^{1,3,4} ; DuPont ^{1,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; Pfizer Inc. ^{1,4} ; NeuroLogic ^{1,3} ; AstraZeneca Pharmaceuticals ¹ ; Bristol-Myers Squibb ^{1,3,4} ; Organon Pharmaceuticals Inc. ¹ ; GlaxoSmithKline ¹ ; Novartis ^{1,4} ; Park-Davis (Warner-Lambert) ^{3,4} ; Abbott Laboratories, Inc. ^{3,4} ; Bayer ^{3,4} ; Pfizer, Inc./Eisai ³ ; Lundbeck ⁴ ; National Institute of Mental Health ³ ; National Institute on Aging ³ ; Cover White Foundation ³ ; Helen Bader Foundation ³ ; Alzheimer Association ³ | 28, 67, 76 |
| JoAnn E. Macbeth, J.D. | American Psychiatric Association ⁶ | 18 |
| Wayne Macfadden, M.D. | AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA ² | 48 |
| Jose R. Maldonado, M.D. | Hospira/Abbott Laboratories, Inc. ³ ; Forest Pharmaceuticals, Inc. ⁴ ; Eli Lilly and Company ⁴ ; Pfizer Inc. ⁴ | 1, 8, 15, 90 |
| Catherine L. Mancini, M.D. | Lundbeck ^{1,3} ; GlaxoSmithKline ^{1,3,4} ; AstraZeneca Pharmaceuticals ³ ; Bristol-Myers Squibb ³ ; Eli Lilly and Company ³ ; Janssen Pharmaceutica Products, LP ³ ; Solvay Pharmaceuticals, Inc. ³ ; Pfizer Inc. ³ | 89 |
| Lauren B. Marangell, M.D. | National Institute of Health ³ ; Stanley Foundation ³ ; Cyberonics, Inc. ^{6,5,3} ; Eli Lilly and Company ^{6,5,3} ; Abbott Laboratories, Inc. ³ ; Pfizer Inc. ¹ ; GlaxoSmithKline ^{1,6} ; Medtronic ¹ ; Forest Pharmaceuticals, Inc. ⁶ ; Wyeth Pharmaceuticals ⁶ | 6 |
| John S. March, M.D. | Pfizer Inc. ^{1,3,4} ; Wyeth Pharmaceuticals ^{1,3} ; Lilly Research Laboratories, a division of Eli Lilly and Company ³ ; Organon Pharmaceuticals Inc. ³ ; AstraZeneca Pharmaceuticals ³ | 31, 42, 66, 92 |
| Stephen R. Marder, M.D. | Janssen Pharmaceutica Products, LP ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Pfizer Inc. ^{1,3,4} | 27, 55, 93 |
| John C. Markowitz, M.D. | Forest Pharmaceuticals, Inc. ³ ; Basic Books ⁶ ; American Psychiatric Publishing ⁶ | 5, 57 |
| Randall D. Marshall, M.D. | Pfizer Inc. ^{3,4,6} ; GlaxoSmithKline ^{3,4,6} ; Wyeth Pharmaceuticals ⁴ | 31, 58, 71 |
| James M. Martinez, M.D. | UCB Pharmaceuticals ¹ ; Cyberonics, Inc. ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; Wyeth Pharmaceuticals ⁴ ; Janssen Pharmaceutica Products, LP ⁴ ; AstraZeneca Pharmaceuticals ⁴ ; Forest Pharmaceuticals, Inc. ⁴ | 4 |
| Prakash S. Masand, M.D. | Forest Pharmaceuticals, Inc. ^{1,3,4,5} ; Janssen Pharmaceutica Products, LP ^{1,3,4,5} ; AstraZeneca Pharmaceuticals ^{3,4} ; Bristol-Myers Squibb ^{1,3,4,5} ; GlaxoSmithKline ^{1,3,4} ; Ortho McNeil Pharmaceutical Inc. ³ ; Wyeth Pharmaceuticals ^{1,3,4} ; Health Care Technology ¹ ; Organon Pharmaceuticals Inc. ¹ ; Pfizer Inc. ^{1,4} ; Abbott Laboratories, Inc. ⁴ ; Eli Lilly and Company ⁵ ; Novartis Pharmaceuticals Corporation ⁴ ; PsychCME Inc. ⁵ | 3, 21, 70 |
| Barbara J. Mason, Ph.D. | Sanofi-Synthelabo Pharmaceuticals, Inc. ¹ ; Somaxon Pharmaceuticals ¹ ; Titan Pharmaceuticals ¹ ; Pfizer Inc. ³ ; Merck & Co., Inc. ¹ ; Forest Pharmaceuticals, Inc. ¹ | 56 |
| Annette M. Matthews, M.D. | Bristol-Myers Squibb ⁶ | 54 |
| Helen S. Mayberg, M.D. | GlaxoSmithKline ¹ ; Cyberonics, Inc. ¹ ; Advanced Neuromodulation Systems ¹ | 12, 27, 46, 54 |
| W. Vaughn McCall, M.S. | Sepracor Inc. ^{1,2,3} ; Sanofi-Synthelabo Pharmaceuticals, Inc. ^{1,3} ; Takeda Pharmaceuticals ³ | 26, 47 |

| Presenter | Manufacturer(s) | Program Page # |
|-------------------------------|---|----------------------------|
| William M. McDonald, M.D. | American Foundation for Suicide Prevention ³ ; National Alliance for Research in Schizophrenia and Depression ³ ; American Foundation for Suicide Prevention ³ ; Fuqua Foundation ³ ; National Institute of Mental Health ³ ; National Institute of Neurological Disease and Stroke ³ ; Neuronetics Inc. ^{3,1} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Organon Pharmaceuticals Inc. ^{3,4} ; Forest Pharmaceuticals, Inc. ^{1,4} ; GlaxoSmithKline ⁴ ; AstraZeneca Pharmaceuticals ⁴ ; Wyeth Pharmaceuticals ⁴ ; Amgen ⁵ ; Teva ⁵ ; Millenium ⁵ ; Pfizer Inc. ⁵ ; Abbott Laboratories, Inc. ⁵ ; Neurobiological Tech. ⁵ | 84 |
| Christopher J. McDougle, M.D. | Janssen Pharmaceutica Products, LP ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Eli Lilly and Company ^{1,3} ; AstraZeneca Pharmaceuticals ³ ; Bristol-Myers Squibb ^{1,3,4} ; Repligen Corp. ^{1,3} | 2, 87 |
| David M. McDowell, M.D. | Wyeth Pharmaceuticals ⁴ ; Bristol-Myers Squibb ⁴ ; Mallinckrodt ⁴ ; Recked-Benheisey ⁴ | 80, 81, 92 |
| Susan L. McElroy, M.D. | Abbott Laboratories, Inc. ¹ ; Bristol-Myers Squibb ^{1,3} ; GlaxoSmithKline ^{1,3} ; Janssen Pharmaceutica Products, LP ¹ ; Eli Lilly and Company ^{1,3} ; Novartis Pharmaceuticals Corporation ¹ ; Ortho McNeil Pharmaceutical Inc. ^{1,3} ; Wyeth Pharmaceuticals ¹ ; Forest Pharmaceuticals, Inc. ³ ; Eisai Inc. ³ ; Merck & Co., Inc. ³ ; Pfizer Inc. ³ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ³ ; UCB Pharmaceuticals ³ ; AstraZeneca Pharmaceuticals ³ | 3, 6 |
| Joseph P. McEvoy, M.D. | AstraZeneca Pharmaceuticals ³ ; Bristol-Myers Squibb ^{3,6} ; GlaxoSmithKline ³ ; Janssen Pharmaceutica Products, LP ^{3,6} ; Eli Lilly and Company ^{1,3,6} ; Pfizer Inc. ^{1,3,6} ; Sanofi-Synthelabo Pharmaceuticals, Inc. ³ | 12 |
| William R. McFarlane, M.D. | Bristol-Myers Squibb ³ | 30 |
| Thomas H. McGlashan, M.D. | Eli Lilly and Company ³ | 30, 77 |
| Jack S. McIntyre, M.D. | Janssen Pharmaceutica Products, LP ⁴ ; GlaxoSmithKline ⁴ ; Eli Lilly and Company ⁴ | 17, 25, 51, 67 |
| Jacqueline M. Melonas, J.D. | Professional Risk Management Services, Inc. ² | 19, 44, 63 |
| Herbert Y. Meltzer, M.D. | ACADIA ¹ ; AstraZeneca Pharmaceuticals ³ ; Bristol-Myers Squibb ^{1,3} ; Eli Lilly and Company ^{1,3} ; Janssen Pharmaceutica Products, LP ^{1,3} ; Novartis Pharmaceuticals Corporation ^{1,3} ; Organon Pharmaceuticals Inc. ^{1,3} ; Pfizer Inc. ^{1,3} ; Solvay Pharmaceuticals, Inc. ^{1,3} ; Sanofi-Synthelabo Pharmaceuticals, Inc. ¹ | 7 |
| Ricardo P. Mendoza, M.D. | AstraZeneca Pharmaceuticals ⁵ | 25 |
| Jeffrey L. Metzner, M.D. | Abbott Laboratories, Inc. ¹ ; AstraZeneca Pharmaceuticals ⁴ | 67, 72 |
| Richard J. Metzner, M.D. | GlaxoSmithKline ⁴ ; Forest Pharmaceuticals, Inc. ⁴ | 90 |
| Eric Mick, Sc.D. | McNeil Consumer Healthcare ⁶ ; Janssen Pharmaceutica Products, LP ¹ | 80 |
| David J. Miklowitz, Ph.D. | Eli Lilly and Company ⁴ | 5 |
| Alexander L. Miller, M.D. | Abbott Laboratories, Inc. ^{3,4} ; Almirall ³ ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ³ ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Pfizer Inc. ³ ; Informedix ¹ | 33, 51 |
| Andrew H. Miller, M.D. | Schering-Plough Corporation ³ ; GlaxoSmithKline ³ ; Janssen Pharmaceutica Products, LP ³ | 20 |
| Del D. Miller, M.D. | Eli Lilly and Company ³ ; Janssen Pharmaceutica Products, LP ⁴ | 33 |
| Mark A. Mintun, M.D. | Molecular Imaging Corp. ⁴ | 9 |
| Jacobo E. Mintzer, M.D. | Voyager Pharmaceutical ³ ; Abbott Laboratories, Inc. ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Boehringer-Ingelheim Pharmaceuticals ^{1,4} ; Bristol-Myers Squibb ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Forest Pharmaceuticals, Inc. ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Johnson and Johnson PRD ³ ; Mitsubishi Pharma Corporation ³ ; Novartis Pharmaceuticals Corporation ³ ; Pfizer Inc. ^{1,3,4} ; Predix ^{1,4} ; Targacept ^{1,4} ; Gerson Lehrman GRP ^{1,4} ; Deutsche Bank ^{1,4} ; Capital Research ^{1,4} ; Paraxel International Corp. ³ ; American Association of Geriatric Psychiatry ¹ ; American Psychiatric Association ¹ ; Alzheimer's Organization (local and national) ¹ ; Eisai Inc. ³ | 55, 64 |
| Karen Miotto, M.D. | Rickett Benckiser ⁴ | 2 |
| Shaila Misri, M.D. | GlaxoSmithKline ^{1,3,4} ; Lundbeck ^{1,3,4} ; Wyeth Pharmaceuticals ^{1,4} ; Biovail Laboratories Inc. ^{1,4} ; AstraZeneca Pharmaceuticals ⁴ | 63 |
| Lisa A. Mistler, M.D. | Schering-Plough Corporation ³ | 29 |
| James E. Mitchell, M.D. | Lilly Research Laboratories, a division of Eli Lilly and Company ³ ; Abbott Laboratories, Inc. ³ | 1, 97 |
| Frederick G. Moeller, M.D. | Ortho McNeil Pharmaceutical Inc. ¹ ; National Institute on Drug Abuse ³ | 97 |
| Rodrigo A. Munoz, M.D. | Eli Lilly and Company ¹ | 18, 33, 61, 67, 82, 87, 93 |
| Philip R. Muskin, M.D. | Bristol-Myers Squibb ^{1,3,4} ; Forest Pharmaceuticals, Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,4} ; Cephalon Inc. ^{1,4} ; Pfizer Inc. ^{1,4} ; AstraZeneca Pharmaceuticals ^{1,4} ; Janssen Pharmaceutica Products ^{1,4} | 22, 28, 51, 67 |
| Hugh Myrick, M.D. | Abbott Laboratories, Inc. ^{1,3,4} ; Forest Pharmaceuticals, Inc. ⁴ ; Ortho McNeil Pharmaceutical Inc. ⁴ ; Bristol-Myers Squibb ⁴ | 62 |
| David Nace, M.D. | Wyeth Pharmaceuticals ^{1,4} ; Bristol-Myers Squibb ¹ ; United Health Group ⁵ | 17 |
| Ziad H. Nahas, M.D. | Neuronetics, Inc. ^{1,3} ; Cyberonics, Inc. ^{1,3} | 51 |

DISCLOSURE INDEX

| Presenter | Manufacturer(s) | Program Page # |
|-------------------------------|--|-----------------------|
| Joseph C. Napoli, M.D. | Solvay Pharmaceuticals, Inc. ³ ; Wyeth Pharmaceuticals ³ ; Bristol-Myers Squibb ³ ; Eli Lilly and Company ³ ; Forest Pharmaceuticals, Inc. ³ ; Janssen Pharmaceutica Products, LP ³ ; Neuronetics, Inc. ³ ; AstraZeneca Pharmaceuticals ^{3,4} ; GlaxoSmithKline ^{3,4} ; Pfizer Inc. ^{3,4} | 14 |
| Jeffrey A. Naser, M.D. | Wyeth Pharmaceuticals ⁴ ; Novartis Pharmaceuticals Corporation ⁴ ; Forest Pharmaceuticals, Inc. ⁴ | 94 |
| George S. Nasra, M.D. | Forest Pharmaceuticals, Inc. ⁴ ; GlaxoSmithKline ⁴ ; Wyeth Pharmaceuticals ⁴ ; Pfizer Inc. ⁴ ; Organon Pharmaceuticals Inc. ⁴ | 92 |
| J. Craig Nelson, M.D. | Abbott Laboratories, Inc. ^{1,4} ; Eli Lilly and Company ^{1,3,4} ; Forest Pharmaceuticals, Inc. ^{3,4} ; GlaxoSmithKline ^{3,4} ; Janssen Pharmaceutica Products, LP ^{3,4} ; Organon Pharmaceuticals Inc. ^{3,1,4} ; Pfizer Inc. ^{1,3,4} ; Wyeth Pharmaceuticals ⁴ ; Bristol-Myers Squibb ¹ ; Orexigen ¹ ; Shire Ridgewood Pharmaceuticals ¹ | 55 |
| Charles B. Nemeroff, M.D. | Abbott Laboratories, Inc. ^{1,3,4} ; American Foundation for Suicide Prevention (AFSP) ³ ; Acadia Pharmaceuticals ¹ ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Corcept ^{1,5} ; Cypress Bioscience, Inc. ¹ ; Cyberonics, Inc. ¹ ; Forest Pharmaceuticals, Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; National Alliance for Research in Schizophrenia and Depression ³ ; National Institute of Mental Health ³ ; Jazz Pharmaceuticals ¹ ; Neurocrine Biosciences Inc. ^{1,5} ; Ono Pharma ¹ ; Otsuka America Pharmaceutical ^{1,4} ; Quintiles ¹ ; Pfizer Inc. ^{3,4} ; Somerset Pharmaceuticals Inc. ¹ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ¹ ; Stanley Foundation/NAMI ³ ; Wyeth Pharmaceuticals ^{1,3,4} ; American Psychiatric Institute for Research and Education (APIRE) ¹ ; George West Health Foundation ¹ ; Novadel Pharma ¹ ; Organon Pharmaceuticals Inc. ⁴ | 42 |
| David N. Neubauer, M.D. | Neurocrine Biosciences Inc./Pfizer Inc. ¹ ; Takeda Pharmaceuticals ¹ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ⁴ | 62 |
| Antonia S. New, M.D. | Eli Lilly and Company ³ | 7, 98 |
| John W. Newcomer, M.D. | Bristol-Myers Squibb ^{3,1} ; Otsuka America Pharmaceutical ³ ; National Institute of Mental Health ³ ; National Alliance for Research in Schizophrenia and Depression ³ ; Sidney Baer Foundation ³ ; Pfizer Inc. ^{3,1} ; Janssen Pharmaceutica Products, LP ^{3,1} ; AstraZeneca Pharmaceuticals ^{1,3} ; Wyeth Pharmaceuticals ¹ ; GlaxoSmithKline ¹ ; Eli Lilly and Company ^{1,3} | 37 |
| Cassandra F. Newkirk, M.D. | Pfizer Inc. ¹ ; Abbott Laboratories, Inc. ⁴ | 43, 49, 66 |
| Anthony T. Ng, M.D. | Pfizer Inc. ⁶ | 2, 19, 43, 61 |
| Andrew A. Nierenberg, M.D. | Cyberonics, Inc. ^{1,3} ; Innapharma ¹ ; Neuronetics, Inc. ¹ ; Shire Ridgewood Pharmaceuticals ¹ ; Eli Lilly and Company ^{1,3} ; GlaxoSmithKline ^{1,3} ; National Institute of Mental Health ^{1,3} ; Bristol-Myers Squibb ³ ; Cederroth ³ ; National Alliance for Research in Schizophrenia and Depression ³ ; Stanley Foundation ³ ; Organon Pharmaceuticals Inc. ⁴ ; Janssen Pharmaceutica Products ¹ , LP; Wyeth Pharmaceuticals ^{1,3} ; Lichtwer ³ | 5, 70, 84 |
| Philip T. Ninan, M.D. | Bristol-Myers Squibb ⁴ ; Cephalon Inc. ^{1,3,4} ; Cyberonics, Inc. ³ ; Eli Lilly and Company ^{1,3} ; Forest Pharmaceuticals, Inc. ^{1,3,4} ; GlaxoSmithKline ^{3,4} ; Janssen Pharmaceutica Products, LP ^{3,4} ; Solvay Pharmaceuticals, Inc. ^{1,3} ; UCB Pharmaceuticals ^{1,3} ; Wyeth Pharmaceuticals ^{1,3,4} ; National Institute of Mental Health ³ ; Pfizer Inc. ³ | 3, 11 |
| Ruta M. Nonacs, M.D. | GlaxoSmithKline ⁴ | 2, 66 |
| Carol S. North, M.D. | UCB Pharmaceuticals ¹ ; GlaxoSmithKline ^{1,4} ; King Pharmaceuticals ¹ | 19 |
| Andrei Novac, M.D. | GlaxoSmithKline ⁴ ; Pfizer Inc. ⁴ ; Forest Pharmaceuticals, Inc. ⁴ | 91 |
| Douglas K. Novins, M.D. | Ortho McNeil Pharmaceutical Inc. ¹ | 50 |
| H. George Nurnberg, M.D. | R.W. Johnson Pharmaceuticals ³ ; LIPHA Pharmaceuticals ³ ; Parke-Davis Pharmaceuticals ³ ; Wyeth Pharmaceuticals ^{3,4} ; Abbott Laboratories, Inc. ^{3,4} ; Pfizer Inc. ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; | 70 |
| R. Michael O'Bannon, Ph.D. | EEG Spectrum International ^{4,5,6} | 63, 74 |
| Charles P. O'Brien, M.D. | Alkermes Pharmaceuticals ¹ ; Drug Abuse Sciences ^{1,5} | 62 |
| Elizabeth OFili, M.D. | Novartis Pharmaceuticals Corporation ^{1,4} ; Sanofi-Synthelabo Pharmaceuticals, Inc. ¹ ; Merck & Co., Inc. ⁴ ; Schering-Plough Corporation ⁴ | 42 |
| Mark Olfson, M.D. | Bristol-Myers Squibb ^{1,3} ; Eli Lilly and Company ³ ; Ortho McNeil Pharmaceutical Inc. ¹ ; Janssen Pharmaceutica Products, LP ⁴ | 51 |
| Mary B. O'Malley, M.D. Ph.D. | Cephalon Inc. ⁴ | 73 |
| Lewis A. Opler, M.D. | Multi-Health Systems, Inc. ⁶ | 8, 18, 92 |
| Patricia I. Ordorica, M.D. | Pfizer Inc. ^{1,4} | 52 |
| Urban P. Osby, M.D. | Bristol-Myers Squibb ³ | 23 |
| Michael J. Ostacher, M.D. | AstraZeneca Pharmaceuticals ^{4,6} ; Forest Pharmaceuticals, Inc. ^{4,6} ; GlaxoSmithKline ^{4,6} | 5 |
| Michael W. Otto, Ph.D. | GlaxoSmithKline ³ ; Pfizer Inc. ³ ; Lilly Research Laboratories, a division of Eli Lilly and Company ³ | 2 |
| Elizabeth Pappadopulos, Ph.D. | Bristol-Myers Squibb ^{1,2} ; Janssen Pharmaceutica Products, LP ⁴ | 2 |

| Presenter | Manufacturer(s) | Program Page # |
|-------------------------------|---|----------------|
| Sagar Parikh, M.D. | Wyeth Pharmaceuticals ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Janssen Pharmaceutica Products, LP-Ortho McNeil Pharmaceutical Inc. ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Biovail Laboratories Inc. ^{1,3,4} ; Novartis Pharmaceuticals Corporation ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} | 74 |
| Joseph J. Parks III, M.D. | Lilly Research Laboratories, a division of Eli Lilly and Company ^{2,3,5} ; Bristol-Myers Squibb ¹ ; Abbott Laboratories, Inc. ³ ; AstraZeneca Pharmaceuticals ³ ; Janssen Pharmaceutica Products, LP ³ | 15 |
| Joseph V. Penn, M.D. | Celltech Pharmaceuticals, Ltd. ⁴ ; Ortho McNeil Pharmaceutical Inc. ⁴ | 78 |
| Jennifer K. Pennell, M.D. | Wyeth Pharmaceuticals ⁶ | 61 |
| Diana O. Perkins, M.D. | Bristol-Myers Squibb ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{3,4} ; Pfizer Inc. ³ ; Otsuka America Pharmaceutical ³ ; AstraZeneca Pharmaceuticals ^{3,4} | 30, 52 |
| Roy H. Perlis, M.D. | Eisai Inc. ³ ; Pfizer Inc. ¹ ; GlaxoSmithKline ⁴ ; Eli Lilly and Company ^{1,4} ; Bristol-Myers Squibb ^{1,4} ; AstraZeneca Pharmaceuticals ^{1,4} ; Elan Pharmaceuticals ³ | 3, 47 |
| Eric D. Pesclow, M.D. | Pfizer Inc. ⁴ ; GlaxoSmithKline ⁴ | 19, 48 |
| Ronald C. Petersen, M.D. | Pfizer Inc. ³ ; Eisai Inc. ³ ; Elan Pharmaceuticals ¹ ; GE Global Research ¹ | 62 |
| Christopher B. Peterson, M.D. | Bristol-Myers Squibb ⁶ | 17 |
| Francois C. Petitjean, M.D. | Bristol-Myers Squibb ¹ ; Janssen Pharmaceutica Products, LP ⁵ | 55 |
| Helen M. Pettinati, Ph.D. | Alkermes Pharmaceuticals ^{1,3} ; AstraZeneca Pharmaceuticals ^{1,3} ; Bristol-Myers Squibb ³ ; Ortho McNeil Pharmaceutical Inc. ³ | 62 |
| Katharine A. Phillips, M.D. | Eli Lilly and Company ³ ; UCB Pharmaceuticals ³ ; Pfizer Inc. ^{3,4} ; Forest Pharmaceuticals, Inc. ^{3,4} | 24, 30 |
| Lawrence S. Phillips, M.D. | Novartis ^{1,3,4} ; Pfizer Inc. ^{1,3} ; Novo Nordisk ³ ; Sankyo ³ ; Lilly Research Laboratories, a division of Eli Lilly and Company ³ | 42 |
| Teresa A. Pigott, M.D. | Lilly Research Laboratories, a division of Eli Lilly and Company ³ ; GlaxoSmithKline ³ ; Pfizer Inc. ³ ; Forest Pharmaceuticals, Inc. ³ | 13 |
| Harold Alan Pincus, M.D. | UPMC Health Plan ¹ | 52 |
| Marie France Poirier, M.D. | Janssen Pharmaceutica Products, LP ³ ; Bristol-Myers Squibb ³ | 55 |
| Mark H. Pollack, M.D. | Bristol-Myers Squibb ¹ ; Cephalon Inc. ^{1,3} ; Forest Pharmaceuticals, Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; Novartis Pharmaceuticals Corporation ¹ ; Otsuka America Pharmaceutical ¹ ; Pfizer Inc. ^{1,3,4} ; Roche Laboratories, a member of the Roche Group ¹ ; UCB Pharmaceuticals ^{1,3} ; Wyeth Pharmaceuticals ^{1,3,4} ; Solvay Pharmaceuticals, Inc. ⁴ ; Sepracor Inc. ¹ | 6, 84 |
| Robert Popozian, Ph.D. | Pfizer Inc. ² | 67 |
| David J. Posey, M.D. | Janssen Pharmaceutica Products, LP ^{3,4} ; Eli Lilly and Company ^{1,3} ; AstraZeneca Pharmaceuticals ³ | 2 |
| Robert M. Post, M.D. | Abbott Laboratories, Inc. ¹ ; AstraZeneca Pharmaceuticals ¹ ; Bristol-Myers Squibb ¹ ; Elan Pharmaceuticals ¹ ; GlaxoSmithKline ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Shire Ridgewood Pharmaceuticals ¹ ; UCB Pharmaceuticals ¹ | 56, 77 |
| William Potter, M.D. | Eli Lilly and Company ⁵ ; Merck & Co., Inc. ² | 84 |
| Ulrich Preuss, M.D. | Eli Lilly and Company ⁶ | 34 |
| Annelle B. Primm, M.D. | Pfizer Inc. ^{1,3,4,6} ; Eli Lilly and Company ¹ ; Janssen Pharmaceutica Products, LP ¹ | 76, 82, 92 |
| India Primm-Spencer | Pfizer Inc. ^{3,4} ; Eli Lilly and Company ¹ | 43 |
| Jefferson B. Prince, M.D. | McNeil Pharmaceutical Inc. ⁴ ; Eli Lilly and Company ⁴ ; Forest Pharmaceuticals, Inc. ⁴ ; GlaxoSmithKline ⁶ ; Shire Ridgewood Pharmaceuticals ⁶ ; Novartis Pharmaceuticals Corporation ⁶ | 1, 5, 51 |
| Peter V. Rabins, M.D. | Pfizer Inc. ^{3,4} ; Eli Lilly and Company ⁴ ; Janssen Pharmaceutica Products, LP ⁴ ; Wyeth Pharmaceuticals ⁴ | 17, 77 |
| Charles Raison, M.D. | Wyeth Pharmaceuticals ⁴ ; Eli Lilly and Company ⁴ ; Schering-Plough Corporation ⁴ | 51 |
| Luis F. Ramirez, M.D. | Bristol-Myers Squibb ⁴ ; Organon Pharmaceuticals Inc. ^{1,4} ; Pfizer Inc. ^{1,4} ; Janssen Pharmaceutica Products, LP ⁴ | 39 |
| Paul M. Ramirez, Ph.D. | Multi-Health Systems Publishers ⁶ | 8 |

DISCLOSURE INDEX

| Presenter | Manufacturer(s) | Program Page # |
|-------------------------------|--|---|
| Mark H. Rapaport, M.D. | Forest Pharmaceuticals, Inc. ^{5,1,3,4} ; Organon Pharmaceuticals Inc. ¹ ; Roche Laboratories, a member of the Roche Group ¹ ; Sumitomo ¹ ; AstraZeneca Pharmaceuticals ³ ; Bristol-Myers Squibb ³ ; Abbott Laboratories, Inc. ³ ; Solvay Pharmaceuticals, Inc. ³ ; Novartis Pharmaceuticals Corporation ³ ; GlaxoSmithKline ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Wyeth Pharmaceuticals ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Sanofi-Synthelabo Pharmaceuticals, Inc. ³ ; Stanley Foundation ³ ; UCB Pharmaceuticals ³ ; National Institute of Mental Health ^{3,1} ; Cyberonics, Inc. ^{1,4} ; Pharmacia Upjohn ^{4,1} ; Neurocrine Biosciences Inc. ¹ ; National Institute on Drug Abuse (NIDA) ¹ | 9, 16, 20, 27 |
| Natalie L. Rasgon, M.D. | Wyeth Pharmaceuticals ^{1,4} ; Forest Pharmaceuticals, Inc. ^{1,3,4} ; Abbott Laboratories, Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,4} ; UCLA General Clinical Research Center Medical Advisory Committee ¹ ; National Institute on Aging ³ ; National Institute of Mental Health ³ ; Eli Lilly and Company ⁴ ; Pfizer Inc. ⁴ ; Novartis Pharmaceuticals Corporation ⁴ | 37, 63 |
| Shanaya Rathod, M.D. | Janssen Cilag Pharmaceuticals Inc. | 92 |
| Norman Relkin, M.D. | Eisai Inc. ^{1,3,4} ; Pfizer Inc. ^{1,4} | 62 |
| Roy O. Resnikoff, M.D. | AstraZeneca Pharmaceuticals ³ ; Bristol-Myers Squibb ³ ; GlaxoSmithKline ³ ; Lilly Research Laboratories, a division of Eli Lilly and Company ³ ; Pfizer Inc. ³ ; Wyeth Pharmaceuticals ³ | 5 |
| Charles F. Reynolds III, M.D. | Forest Pharmaceuticals, Inc. ³ ; GlaxoSmithKline ³ ; Pfizer Inc. ³ | 30, 94 |
| Michelle B. Riba, M.D. | Eli Lilly and Company ¹ | 8, 10, 13, 17, 28, 35, 43, 49, 53, 67, 83, 92, 93 |
| Gary S. Richardson, M.D. | King Pharmaceutical ¹ ; Neurocrine Biosciences Inc./Pfizer Inc. ^{3,1} ; Sepracor Inc. ^{1,3} ; Takeda Pharmaceuticals ^{1,3} ; Sanofi-Synthelabo Pharmaceuticals, Inc. ⁴ | 62 |
| Michael J. Robinson, M.D. | Eli Lilly and Company ² | 40 |
| Rebecca L. Robinson, M.S. | Eli Lilly and Company ² | 89 |
| Robert G. Robinson, M.D. | Forest Pharmaceuticals, Inc. ⁴ | 32 |
| Steven P. Roose, M.D. | Wyeth Pharmaceuticals ^{1,2} ; Forest Pharmaceuticals, Inc. ^{1,2} ; Bristol-Myers Squibb ¹ ; Eli Lilly and Company ^{1,2} ; Organon Pharmaceuticals Inc. ² | 2, 6, 94 |
| Jerrold F. Rosenbaum, M.D. | Pfizer Inc. ¹ ; Bristol-Myers Squibb ¹ ; Cyberonics, Inc. ¹ ; Eli Lilly and Company ¹ ; Forest Pharmaceuticals, Inc. ^{1,4} ; GlaxoSmithKline ¹ ; Janssen Pharmaceutica Products, LP ⁴ ; Organon Pharmaceuticals Inc. ⁴ ; Somerset Pharmaceuticals Inc. ¹ ; Wyeth Pharmaceuticals ^{1,4} | 1 |
| Michael B. Rosenbluth, M.D. | Wyeth Pharmaceuticals ⁴ ; Organon Pharmaceuticals Inc. ⁴ ; Eli Lilly and Company ⁴ ; Johnson and Johnson PRD ⁴ | 32 |
| Miriam Rosenthal, M.D. | Pfizer Inc. ⁴ ; Forest Pharmaceuticals, Inc. ⁴ | 69 |
| Norman E. Rosenthal, M.D. | GlaxoSmithKline ^{1,3} | 31, 61 |
| Richard N. Rosenthal, M.D. | Alkermes Pharmaceuticals ¹ ; Forest Pharmaceuticals, Inc. ^{1,4} | 83 |
| Thomas J. Rosko, M.D. | Pfizer Inc. ⁴ | 87 |
| Anthony L. Rostain, M.D. | Ortho McNeil Pharmaceutical Inc. ⁴ ; Eli Lilly and Company ⁴ | 22, 68, 85 |
| Anthony J. Rothschild, M.D. | Cephalon Inc. ³ ; Wyeth Pharmaceuticals ³ ; Forest Pharmaceuticals, Inc. ⁴ ; Pfizer Inc. ⁴ ; Eli Lilly and Company ^{3,4} ; Bristol-Myers Squibb ^{3,4} ; Abbott Laboratories, Inc. ⁴ | 16, 41, 55 |
| Peter P. Roy-Byrne, M.D. | GlaxoSmithKline ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Forest Pharmaceuticals, Inc. ^{1,3,4} ; Alza/McNeil Pharmaceuticals ¹ ; Cephalon Inc. ¹ ; Eli Lilly and Company ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Pharmacia ¹ ; Roche Laboratories, a member of the Roche Group ¹ ; Wyeth Pharmaceuticals ^{1,4} ; Novartis Pharmaceuticals Corporation ⁴ | 1, 3 |
| A. John Rush, M.D. | GlaxoSmithKline ^{1,4} ; Robert Wood Johnson Foundation ³ ; National Institute of Mental Health ³ ; Cyberonics, Inc. ^{1,4} ; Stanley Foundation ³ ; Bristol-Myers Squibb ¹ ; Eli Lilly and Company ^{1,4} ; Forest Pharmaceuticals, Inc. ^{1,4} ; Organon Pharmaceuticals Inc. ¹ ; Urban Institute ¹ | 6, 31 |
| Leo J. Russo, Ph.D. | Johnson & Johnson PRD ² | 54 |
| Gary S. Sachs, M.D. | Abbott Laboratories, Inc. ^{1,3} ; GlaxoSmithKline ¹ ; Eli Lilly and Company ¹ ; Janssen Pharmaceutica Products, LP ^{1,3} ; Bristol-Myers Squibb ¹ ; Novartis Pharmaceuticals Corporation ¹ ; Elan Pharmaceuticals ¹ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ¹ ; Sigma-Tau ¹ ; AstraZeneca Pharmaceuticals ¹ ; Solvay Pharmaceuticals, Inc. ¹ ; Pfizer Inc. ¹ | 5, 11, 23, 31, 55, 76 |
| Harold A. Sackeim, Ph.D. | MECTA Corp. ^{1,3} ; Neurocrine Biosciences Inc. ^{1,3} ; Cyberonics, Inc. ^{1,3} ; Magstim Corp. ³ | 6, 47 |
| Martha Sajatovic, M.D. | Eli Lilly and Company ^{1,3} ; GlaxoSmithKline ^{1,4} ; AstraZeneca Pharmaceuticals ^{1,4} ; Bristol-Myers Squibb ^{1,3,4} ; Abbott Laboratories, Inc. ³ ; Pfizer Inc. ⁴ ; Janssen Pharmaceutica Products, LP ⁴ | 64 |
| David Satcher, M.D. | Johnson & Johnson PRD ⁶ | 30 |
| Lawrence Scahill, Ph.D. | Janssen Pharmaceutica Products, LP ^{1,4} ; Pfizer Inc. ¹ ; Bristol-Myers Squibb ¹ | 61 |

| Presenter | Manufacturer(s) | Program Page # |
|---------------------------------|--|------------------------------|
| Alan F. Schatzberg, M.D. | Abbott Laboratories, Inc. ¹ ; Aventis Pharmaceuticals ¹ ; Bristol-Myers Squibb ^{1,3} ; Corcept Therapeutics ^{1,5} ; Eli Lilly and Company ^{1,3} ; Forest Pharmaceuticals, Inc. ^{1,5} ; GlaxoSmithKline ¹ ; Innapharma ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Merck & Co., Inc. ^{1,5} ; Novartis Pharmaceuticals Corporation ¹ ; Organon Pharmaceuticals Inc. ¹ ; Pharmacia ¹ ; Solvay Pharmaceuticals, Inc. ¹ ; Somerset Pharmaceuticals Inc. ¹ ; Wyeth Pharmaceuticals ^{1,3} ; Cypress Bioscience, Inc. ⁵ ; Elan Pharmaceuticals ⁵ ; Pfizer Inc. ⁵ | 9, 16, 33, 45 |
| Randolph B. Schiffer, M.D. | Pfizer Inc. ⁵ ; Janssen Pharmaceutica Products, LP ³ | 1 |
| Christian Schmahl, M.D. | Eli Lilly and Company ^{1,3} | 7, 97, 98 |
| Christopher D. Schneck, M.D. | AstraZeneca Pharmaceuticals ^{1,4} ; Bristol-Myers Squibb ^{1,3} ; UCB Pharmaceuticals ¹ | 5 |
| Lon Schneider, M.D. | Bristol-Myers Squibb ¹ ; Forest Pharmaceuticals, Inc. ¹ ; Janssen Pharmaceutica Products, LP ¹ ; AstraZeneca Pharmaceuticals ¹ | 76 |
| Franklin R. Schneier, M.D. | Forest Pharmaceuticals, Inc. ³ ; Pfizer Inc. ⁴ ; UCB Pharmaceuticals ³ | 3 |
| Nina R. Schooler, Ph.D. | Janssen Pharmaceutica Products, LP ^{1,3} ; Bristol-Myers Squibb ^{1,3} ; AstraZeneca Pharmaceuticals ³ ; Eli Lilly and Company ^{3,1} ; Pfizer Inc. ^{1,3} ; Johnson and Johnson PRD ¹ ; Organon Pharmaceuticals Inc. ¹ | 10 |
| Marc A. Schuckit, M.D. | Ortho McNeil Pharmaceutical Inc. ¹ ; Forest Pharmaceuticals, Inc. ¹ | 56 |
| S. Charles Schulz, M.D. | AstraZeneca Pharmaceuticals ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; Abbott Laboratories, Inc. ³ ; Janssen Pharmaceutica Products, LP ³ | 7, 80 |
| Thomas L. Schwartz, M.D. | Wyeth Pharmaceuticals ^{1,4} ; Cephalon Inc. ³ ; Bristol-Myers Squibb ³ | 37, 70 |
| Larry J. Seidman, Ph.D. | Shire Ridgewood Pharmaceuticals ^{1,3} ; Eli Lilly and Company ^{1,3} ; Janssen Pharmaceutica Products, LP ³ | 57 |
| Michael J. Sernyak, M.D. | AstraZeneca Pharmaceuticals ³ ; Janssen Pharmaceutica Products, LP ¹ ; Eli Lilly and Company ¹ ; Pfizer Inc. ¹ | 55 |
| David D. Servan-Schreiber, M.D. | Institute Francais d'EMDR ⁴ | 94 |
| Peter A. Shapiro, M.D. | Pfizer Inc. ⁴ | 40, 67 |
| Tonmoy Sharma, M.D. | Pfizer Inc. ³ | 23, 89 |
| Shawn C. Shea, M.D. | GlaxoSmithKline ⁴ | 64 |
| M. Katherine Shear, M.D. | Eli Lilly and Company ⁴ ; Forest Pharmaceuticals, Inc. ^{1,3,4} ; Pfizer Inc. ^{1,3,4} | 6, 31, 41 |
| David S. Sheps, M.D. | Pfizer Inc. ^{3,4} | 53 |
| Larry J. Siever, M.D. | Ortho McNeil Pharmaceutical Inc. ^{1,6} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} | 3, 7, 22, 33, 57, 80, 97, 98 |
| Joel M. Silberberg, M.D. | Abbott Laboratories, Inc. ⁴ ; Pfizer Inc. ⁴ ; Eli Lilly and Company ⁴ | 26 |
| Samuel M. Silverman, M.D. | Reckitt Benckiser Pharmaceuticals ¹ | 73 |
| Gregory E. Simon, M.D. | Pfizer Inc. ¹ ; Wyeth Pharmaceuticals ³ ; Eli Lilly and Company ³ | 98 |
| Naomi M. Simon, M.D. | AstraZeneca Pharmaceuticals ³ ; Cephalon Inc. ³ ; Forest Pharmaceuticals, Inc. ^{3,4} ; Janssen Pharmaceutica Products, LP ³ ; Lilly Research Laboratories, a division of Eli Lilly and Company ³ ; Pfizer Inc. ⁴ ; UCB Pharmaceuticals ³ ; Wyeth Pharmaceuticals ³ | 1, 11, 41 |
| Samuel G. Siris, M.D. | Eli Lilly and Company ^{1,4} ; Merck & Co., Inc. ^{1,4} ; Novartis Pharmaceuticals Corporation ⁴ ; Pfizer Inc. ⁴ ; Proctor & Gamble Pharmaceuticals/Aventis Pharmaceuticals ⁴ | 33 |
| Christine Skotzko, M.D. | Pfizer Inc. ⁴ ; AstraZeneca Pharmaceuticals ⁴ | 44 |
| Claudio N. Soares, M.D. | Pfizer Inc. ⁴ ; Sepracor Inc. ¹ ; Wyeth Pharmaceuticals ^{1,4} ; Forest Pharmaceuticals, Inc. ^{1,4} ; GlaxoSmithKline ^{1,4} | 36, 37, 39 |
| H. Brent Solvason, M.D. | Forest Pharmaceuticals, Inc. ^{3,4} ; Eli Lilly and Company ^{3,4} ; Pfizer Inc. ⁴ ; Cephalon Inc. ^{3,4} | 37 |
| Shamsah B. Sonawalla, M.D. | Forest Pharmaceuticals, Inc. ³ | 32 |
| Thomas J. Spencer, M.D. | Abbott Laboratories, Inc. ^{1,3,4} ; Alza/McNeil Pharmaceuticals ^{1,3,4} ; Boston Life Sciences ^{1,3,4} ; Cephalon Inc. ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; Celltech Pharmaceuticals, Ltd. ^{1,3,4} ; Eisai Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Gliatech ^{1,3,4} ; Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; Ortho McNeil Pharmaceutical Inc. ^{1,3,4} ; Novartis Pharmaceuticals Corporation ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Shire Ridgewood Pharmaceuticals ^{1,3,4} ; Solvay Pharmaceuticals, Inc. ^{1,3,4} ; Wyeth Pharmaceuticals ^{1,3,4} | 11, 12, 32, 57 |
| Margaret G. Spinelli, M.D. | Pfizer Inc. ⁴ | 2 |
| Murray B. Stein, M.D. | Eli Lilly and Company ^{1,3,4} ; Forest Pharmaceuticals, Inc. ^{1,3} ; Novartis Pharmaceuticals Corporation ³ ; Pfizer Inc. ^{1,3} ; GlaxoSmithKline ^{1,3,4} ; Solvay Pharmaceuticals, Inc. ^{1,3,4} ; UCB Pharmaceuticals ^{1,3} ; Wyeth Pharmaceuticals ^{1,3,4} ; Alza/McNeil Pharmaceuticals ¹ ; Allergan ¹ ; Alexza Molecular Delivery ¹ ; AstraZeneca Pharmaceuticals ¹ ; Bristol-Myers Squibb ¹ ; Cephalon Inc. ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Hoffmann-La Roche Pharmaceuticals ¹ ; Johnson and Johnson PRD ¹ ; Vela Pharmaceuticals ¹ | 3, 84 |
| Donna E. Stewart, M.D. | Eli Lilly and Company ^{1,3,4} ; Wyeth Pharmaceuticals ^{1,4} | 24, 33, 40, 93 |
| Nada L. Stotland, M.D. | GlaxoSmithKline ⁴ | 8, 15, 49, 83, 85 |

DISCLOSURE INDEX

| Presenter | Manufacturer(s) | Program Page # |
|---------------------------------|---|-----------------------|
| Zachary N. Stowe, M.D. | GlaxoSmithKline ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Wyeth Pharmaceuticals ^{3,4} ; Eli Lilly and Company ⁴ | 63, 85, 99 |
| Eric C. Strain, M.D. | Reckitt Benckiser Pharmaceuticals ⁶ | 14 |
| Joshua Straus, M.D. | Pfizer Inc. ¹ | 63 |
| Joel Streim, M.D. | AstraZeneca Pharmaceuticals ^{1,3} ; Bristol-Myers Squibb ^{1,3} ; Forest Pharmaceuticals, Inc. ^{1,3} ; Janssen Pharmaceutica Products, LP ¹ | 1, 64 |
| Thomas S. Stroup, M.D. | Eli Lilly and Company ³ | 12 |
| Scott Stuart, M.D. | Eli Lilly and Company ⁴ ; Pfizer Inc. ⁴ ; Wyeth Pharmaceuticals ⁴ | 19, 54, 64 |
| Donna M. Sudak, M.D. | GlaxoSmithKline ⁴ | 98 |
| David L. Sultzer, M.D. | Pfizer Inc. ^{3,4} ; Forest Pharmaceuticals, Inc. ^{3,4} ; Janssen Pharmaceutica Products, LP ⁴ ; Abbott Laboratories, Inc. ⁴ ; Bristol-Myers Squibb ⁴ ; AstraZeneca Pharmaceuticals ⁴ | 4, 13 |
| Calvin R. Sumner, M.D. | Eli Lilly and Company ^{2,5} | 34 |
| Trisha Suppes, M.D. | Abbott Laboratories, Inc. ^{1,3,4} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; National Institute of Mental Health ³ ; Novartis Pharmaceuticals Corporation ^{1,3,4} ; R.W. Johnson Pharmaceuticals ³ ; Stanley Foundation ³ ; Eli Lilly and Company ^{1,4} ; Johnson and Johnson PRD ^{1,4} ; Pfizer Inc. ^{1,4} ; Pharmaceutical Research Institute (PRI) ^{1,4} ; Ortho McNeil Pharmaceutical Inc. ^{1,4} ; UCB Pharmaceuticals ^{1,4} | 4, 11 |
| James M. Swanson, M.D. | Celgene ^{1,2,3,4} ; Novartis Pharmaceuticals Corporation ^{1,3,4} ; Celltech Pharmaceuticals, Ltd. ^{1,3,4} ; Cephalon Inc. ^{1,3,4} ; Alza/McNeil Pharmaceuticals ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; McNeil Consumer Healthcare ^{1,3,4} ; Shire Ridgewood Pharmaceuticals ^{1,3,4} ; Targacept ¹ | 48 |
| Marvin S. Swartz, M.D. | Eli Lilly and Company ³ | 28, 81 |
| Rajiv Tandon, M.D. | AstraZeneca Pharmaceuticals ^{1,4} ; Bristol-Myers Squibb ^{1,4} ; Eli Lilly and Company ^{1,4} ; Pfizer Inc. ^{1,4} ; Janssen Pharmaceutica Products, LP ^{1,4} | 15, 27 |
| Andre Tapp, M.D. | AstraZeneca Pharmaceuticals ^{3,4} ; Eli Lilly and Company ⁴ ; Janssen Pharmaceutica Products ⁴ | 33 |
| Pierre N. Tariot, M.D. | Novartis Pharmaceuticals Corporation ¹ ; Bristol-Myers Squibb ^{1,3} ; Eli Lilly and Company ^{1,3} ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Forest Pharmaceuticals, Inc. ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} | 39, 47, 62, 77 |
| Humberto Temporini, M.D. | Pfizer Inc. ⁴ ; AstraZeneca Pharmaceuticals ⁴ | 26 |
| Michael E. Thase, M.D. | Bristol-Myers Squibb ¹ ; Cephalon Inc. ¹ ; Cyberonics, Inc. ¹ ; Forest Pharmaceuticals, Inc. ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Novartis Pharmaceuticals Corporation ¹ ; Pfizer Inc. ¹ ; AstraZeneca Pharmaceuticals ^{1,4} ; Eli Lilly and Company ^{1,4} ; GlaxoSmithKline ^{1,4} ; Organon Pharmaceuticals Inc. ^{1,4} ; Wyeth Pharmaceuticals ^{1,4} | 26, 70 |
| Timothy L. Thistlethwaite, M.D. | Eli Lilly and Company ⁴ ; GlaxoSmithKline ⁴ | 67 |
| Maria L.A. Tiamson, M.D. | Janssen Pharmaceutica Products, LP ⁴ | 88 |
| Martin G. Tracy, J.D. | Professional Risk Management Services, Inc. ² | 19, 44 |
| Robert L. Trestman, M.D. | Abbott Laboratories, Inc. ^{1,3} | 26, 73 |
| Madhukar H. Trivedi, M.D. | Abbott Laboratories, Inc. ³ ; Akzo (Organon Pharmaceuticals Inc.) ^{3,4} ; Bayer ³ ; Bristol-Myers Squibb ^{3,4} ; Eli Lilly and Company ^{3,4} ; Forest Pharmaceuticals, Inc. ^{3,4} ; GlaxoSmithKline ³ ; Janssen Pharmaceutica Products, LP ^{3,4} ; Johnson and Johnson PRD ³ ; Parke-Davis Pharmaceuticals ³ ; National Institute of Mental Health ³ ; Meade Johnson ³ ; Pharmacia & Upjohn ^{3,4} ; Solvay Pharmaceuticals, Inc. ^{3,4} ; Wyeth Pharmaceuticals ^{3,4} ; National Alliance for Research in Schizophrenia and Depression ³ | 4, 67, 73 |
| Paula T. Trzepacz, M.D. | Eli Lilly and Company ² | 12, 76 |
| John W. Tsuang, M.D. | Abbott Laboratories, Inc. ⁴ ; Janssen Pharmaceutica Products, LP ⁴ ; Eli Lilly and Company ⁴ | 2 |
| Phebe M. Tucker, M.D. | GlaxoSmithKline ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} ; Ortho McNeil Pharmaceutical Inc. ^{3,4} ; Pfizer Inc. ³ | 2 |
| Tim Tully, Ph.D. | Helicon Therapeutics, Inc. ^{1,5} | 81 |
| Sandra L. Tunis, Ph.D. | Eli Lilly and Company ^{2,3} | 25 |
| Robert J. Ursano, M.D. | Abbott Laboratories, Inc. ³ | 19, 95 |
| Michael A. Van Ameringen, M.D. | Biovail Laboratories Inc. ¹ ; Cephalon Inc. ¹ ; Novartis Pharmaceuticals Corporation ¹ ; AstraZeneca Pharmaceuticals ^{1,3} ; Solvay Pharmaceuticals, Inc. ^{1,3} ; Wyeth Pharmaceuticals ^{1,3} ; GlaxoSmithKline ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Bristol-Myers Squibb ³ ; Eli Lilly and Company ³ ; Lundbeck ³ | 90 |
| Donna Vanderpool, J.D. | Professional Risk Management Services, Inc. ² | 19 |
| Kaycia L. Vansickle, M.D. | Pfizer Inc. ⁴ ; AstraZeneca Pharmaceuticals ⁴ ; Wyeth Pharmaceuticals ⁴ | 64 |
| Dawn I. Velligan, Ph.D. | AstraZeneca Pharmaceuticals ^{1,3,4} ; Bristol-Myers Squibb ^{1,3} ; Eli Lilly and Company ^{1,3} ; InfoMedix ¹ ; Janssen Pharmaceutica Products, LP ^{1,3} ; Pfizer Inc. ^{1,3,4} | 87 |
| George I. Viamontes, M.D. | Johnson and Johnson PRD ⁵ ; Pfizer Inc. ¹ ; GlaxoSmithKline ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Bristol-Myers Squibb ¹ ; Wyeth Pharmaceuticals ¹ | 27, 68 |

| Presenter | Manufacturer(s) | Program Page # |
|------------------------------|---|------------------------------|
| Adele C. Viguera, M.D. | GlaxoSmithKline ⁴ | 66, 99 |
| Albert V. Vogel, M.D. | Joint Commission on Accreditation of Healthcare Organization ⁶ | 72 |
| Karen D. Wagner, M.D. | Abbott Laboratories, Inc. ^{1,3,4} ; Eli Lilly and Company ^{1,3,4} ; Forest Pharmaceuticals, Inc. ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,4} ; Novartis Pharmaceuticals Corporation ^{1,4} ; Pfizer Inc. ^{1,3,4} ; Bristol-Myers Squibb ^{1,3} ; National Institute of Mental Health ^{1,3} ; Otsuka America Pharmaceutical ¹ ; UCB Pharmaceuticals ¹ ; Wyeth Pharmaceuticals ^{1,3} ; Organon Pharmaceuticals Inc. ³ ; Ortho McNeil Pharmaceutical Inc. ⁶ | 4, 63 |
| John T. Walkup, M.D. | Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; Pfizer Inc. ^{3,4} ; Abbott Laboratories, Inc. ³ ; Janssen Pharmaceutica Products, LP ⁴ | 42, 68, 93 |
| B. Timothy Walsh, M.D. | Eli Lilly and Company ³ ; Ortho McNeil Pharmaceutical Inc. ³ | 59, 71 |
| G. Scott Waterman, M.D. | Lilly Research Laboratories, a division of Eli Lilly and Company ³ ; Bristol-Myers Squibb ³ | 33 |
| Peter J. Weiden, M.D. | Bristol-Myers Squibb ^{1,3,4} ; Otsuka America Pharmaceutical ³ ; AstraZeneca Pharmaceuticals ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} | 51, 87 |
| Daniel R. Weinberger, M.D. | Bristol-Myers Squibb ¹ ; AstraZeneca Pharmaceuticals ¹ ; Janssen Pharmaceutica Products, LP ¹ ; Eli Lilly and Company ¹ ; Otsuka America Pharmaceutical ¹ ; Pfizer Inc. ¹ | 11, 52 |
| Richard D. Weiner, M.D. | Mecta Corp. ⁴ | 26 |
| Margaret D. Weiss, M.D. | Johnson and Johnson PRD ¹ ; Pharmacia & Upjohn Company, Inc. ¹ ; Purdue Pharma L.P. ^{1,3} ; Eli Lilly and Company ^{1,3,4} ; Novartis Pharmaceuticals Corporation ^{1,3,4} ; Shire Ridgewood Pharmaceuticals ^{1,3,4} ; GlaxoSmithKline ³ ; Circa Dia ³ | 23, 32 |
| Steven Wengel, M.D. | Pfizer Inc. ⁴ ; Forest Pharmaceuticals, Inc. ⁴ | 64 |
| Sharon B. Wigal, Ph.D. | Alza/McNeil Pharmaceuticals ^{1,3,4} ; McNeil Consumer & Specialty Pharmaceuticals ^{1,3,4} ; Celltech Pharmaceuticals, Ltd. ^{1,3,4} ; Novartis Pharmaceuticals Corporation ^{1,3,4} ; Shire Ridgewood Pharmaceuticals ^{1,3,4} ; Celgene ^{3,4} ; Cephalon Inc. ^{3,4} ; Eli Lilly and Company ^{3,4} ; Janssen Pharmaceutica Products, LP ³ | 62 |
| Timothy E. Wilens, M.D. | Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; Abbott Laboratories, Inc. ^{1,3,4} ; Alza/McNeil Pharmaceuticals ^{1,3,4} ; Celltech Pharmaceuticals, Ltd. ^{1,3,4} ; GlaxoSmithKline ^{1,3,4} ; National Institute on Drug Abuse ^{1,3,4} ; National Institute of Mental Health ^{1,3,4} ; NICMH ^{1,3,4} ; Neurosearch ^{1,3,4} ; Pfizer Inc. ^{1,3,4} ; Shire Ridgewood Pharmaceuticals ^{1,3,4} | 12, 22, 62, 80 |
| Jill Williams, M.D. | Pfizer Inc. ³ | 26 |
| John W. Winkelman, M.D. | Cephalon Inc. ^{1,4} ; GlaxoSmithKline ^{1,3,4} ; Pfizer Inc. ^{1,3} ; UCB Pharmaceuticals ³ ; Sanofi-Synthelabo Pharmaceuticals, Inc. ^{4,1} ; Eli Lilly and Company ⁴ ; Elan Pharmaceuticals ¹ ; King Pharmaceutical ^{1,4} ; Sepracor Inc. ¹ ; Boehringer-Ingelheim Pharmaceuticals ³ ; Novartis Pharmaceuticals Corporation ¹ ; Schwarz ¹ | 9, 26, 37, 53 |
| Katherine L. Wisner, M.D. | Pfizer Inc. ⁴ ; GlaxoSmithKline ⁴ | 2, 23, 30, 41, 58 |
| Madelaine M. Wohlreich, M.D. | Eli Lilly and Company ² | 90 |
| William C. Wood, M.D. | Aventis ¹ ; Genomic Health ¹ | 49 |
| Scott W. Woods, M.D. | Bristol-Myers Squibb ³ ; UCB Pharmaceuticals ³ | 30 |
| Janet Wozniak, M.D. | Janssen Pharmaceutica Products, LP ⁴ ; Eli Lilly and Company ^{3,4} ; Shire Ridgewood Pharmaceuticals ¹ | 35 |
| Jesse H. Wright, M.D. | Mindstreet ^{5,6} ; Eli Lilly and Company ⁶ | 8, 26, 50 |
| Joel Yager, M.D. | Ortho McNeil Pharmaceutical Inc. ¹ ; Janssen Pharmaceutica Products, LP ⁶ | 1, 6, 17, 25, 45, 68, 83, 97 |
| Kimberly A. Yonkers, M.D. | Berlex Laboratories, Inc. ^{1,3} ; GlaxoSmithKline ^{1,3} ; Wyeth Pharmaceuticals ¹ ; Pfizer Inc. ¹ ; National Institute on Drug Abuse ³ ; National Institute of Mental Health ³ ; HRSA ³ | 13, 30 |
| Mary Zanmarini, Ed.D. | Eli Lilly and Company ^{1,3} | 7 |
| Phyllis C. Zee, M.D. | Sanofi-Synthelabo Pharmaceuticals, Inc. ⁴ ; Takeda Pharmaceuticals ^{1,3} | 9, 53 |
| Douglas M. Ziedonis, M.D. | Lilly Research Laboratories, a division of Eli Lilly and Company ^{1,3,4} ; Janssen Pharmaceutica Products, LP ^{1,3,4} ; Bristol-Myers Squibb ^{1,3,4} | 26 |
| Robert B. Zipursky, M.D. | Eli Lilly and Company ^{3,4} ; Novartis Pharmaceuticals Corporation ^{4,3} ; AstraZeneca Pharmaceuticals ^{3,4} ; Pfizer Inc. ⁵ | 10, 12 |
| Sidney Zisook, M.D. | GlaxoSmithKline ^{1,4} ; AstraZeneca Pharmaceuticals ⁴ ; Janssen Pharmaceutica Products, LP ⁴ ; Pfizer Inc. ⁴ ; Eli Lilly and Company ⁴ ; Wyeth Pharmaceuticals ⁴ ; Forest Pharmaceuticals, Inc. ⁴ | 31, 82 |
| Joseph Zohar, M.D. | Solvay Pharmaceuticals, Inc. ³ ; Eli Lilly and Company ³ | 79 |